1	Identifying molecular mediators of the relationship between body mass index and
2	endometrial cancer risk: a Mendelian randomization analysis
3	
4	Emma Hazelwood ^{1,2} , Eleanor Sanderson ^{1,2} , Vanessa Y Tan ^{1,2} , Katherine S Ruth ³ , Timothy M Frayling ⁴ , Niki
5	Dimou ⁵ , Marc J Gunter ⁵ , Laure Dossus ⁵ , Claire Newton ⁶ , Neil Ryan ^{6,7} , Dimitri J Pournaras ⁸ , Tracy A
6	O'Mara ⁹ , George Davey Smith ^{1,2} , Richard M Martin ^{1,2,10} , James Yarmolinsky ^{1,2}
7	
8	¹ MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK
9	² Bristol Medical School, University of Bristol, Bristol, UK
10	³ University of Exeter Medical School, University of Exeter, Exeter, UK
11	4 Genetics of Complex Traits, College of Medicine and Health, University of Exeter, Exeter, UK
12	5 Nutrition and Metabolism Branch, International Agency for Research on Cancer, Lyon, France
13	⁶ Department of Gynecology, St Michaels Hospital University Hospitals Bristol NHS Foundation Trust,
14	Bristol, UK
15	⁷ The Academic Women's Health Unit, Translational Health Sciences, Bristol Medical School, University of
16	Bristol, Bristol, UK
17	⁸ Department of Upper GI and Bariatric/Metabolic Surgery, North Bristol NHS Trust, Southmead Hospital,
18	Bristol, UK
19	⁹ Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute,
20	Brisbane, Queensland, Australia
21	¹⁰ National Institute for Health Research Bristol Biomedical Research Centre, University of Bristol,
22	University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK
23	

24 Corresponding author:

- 25 James Yarmolinsky, PhD
- 26 MRC Integrative Epidemiology Unit
- 27 Population Health Sciences
- 28 Bristol Medical School
- 29 University of Bristol
- зо Bristol, UK
- 31 james.yarmolinsky@bristol.ac.uk

32 Abstract

33	Background: Endometrial cancer is the most common gynaecological cancer in high-income countries.
34	Elevated body mass index (BMI) is an established modifiable risk factor for this condition and is
35	estimated to confer a larger effect on endometrial cancer risk than any other cancer site. However, the
36	molecular mechanisms underpinning this association remain unclear. We used Mendelian
37	randomization (MR) to evaluate the causal role of 14 molecular risk factors (hormonal, metabolic, and
38	inflammatory markers) in endometrial cancer risk. We then evaluated and quantified the potential
39	mediating role of these molecular traits in the relationship between BMI and endometrial cancer.
40	Matha da and Findinga, Canatia instrumento ta grann 14 malandar rial factore and DMI ware
40	Methods and Findings: Genetic instruments to proxy 14 molecular risk factors and BMI were
41	constructed by identifying single-nucleotide polymorphisms (SNPs) reliably associated ($P < 5.0 \times 10^{-8}$)
42	with each respective risk factor in previous genome-wide association studies (GWAS). Summary
43	statistics for the association of these SNPs with overall and subtype-specific endometrial cancer risk
44	(12,906 cases and 108,979 controls) were obtained from a GWAS meta-analysis of the Endometrial
45	Cancer Association Consortium (ECAC), Epidemiology of Endometrial Cancer Consortium (E2C2), and UK
46	Biobank. SNPs were combined into multi-allelic models and odds ratios (ORs) and 95% confidence
47	intervals (95% Cls) were generated using inverse-variance weighted random-effects models. The
48	mediating roles of the molecular risk factors in the relationship between BMI and endometrial cancer
49	were then estimated using multivariable MR. In MR analyses, there was strong evidence that BMI (OR
50	per SD increase: 1.88, 95% CI: 1.69 to 2.09, $P = 3.87 \times 10^{-31}$), total testosterone (OR per inverse normal
51	transformed nmol/L increase: 1.64, 95% CI: 1.43 to 1.88, $P = 1.71 \times 10^{-12}$), bioavailable testosterone (OR
52	per inverse normal transformed nmol/L increase: 1.46, 95% CI: 1.29 to 1.65, $P = 3.48 \times 10^{-9}$), fasting
53	insulin (OR per natural log transformed pmol/L increase: 3.93, 95% CI: 2.29 to 6.74, $P = 7.18 \times 10^{-7}$) and
54	sex hormone-binding globulin (SHBG, OR per inverse normal transformed nmol/L increase: 0.71, 95% CI:

0.59 to 0.85, $P = 2.07 \times 10^{-4}$) had a causal effect on endometrial cancer risk. Additionally, there was 55 suggestive evidence that total serum cholesterol (OR per mg/dL increase: 0.90, 95% CI: 0.81 to 1.00, P =56 4.01 x 10⁻²) had an effect on endometrial cancer risk. In mediation analysis using multivariable MR, we 57 found evidence for a mediating role of fasting insulin (19% total effect mediated, 95% CI: 5 to 34%, P = 58 9.17 x 10^{-3}), bioavailable testosterone (15% mediated, 95% CI: 10 to 20%, P = 1.43 x 10^{-8}), and SHBG (7% 59 mediated, 95% CI: 1 to 12%, $P = 1.81 \times 10^{-2}$) in the relationship between BMI and endometrial cancer 60 risk. The primary limitations of this analysis include the assumption of linear relationships across 61 univariable and multivariable analyses and the restriction of analyses to individuals of European 62 ancestry. 63

Conclusions: Our comprehensive Mendelian randomization analysis provides insight into potential
 causal mechanisms linking BMI with endometrial cancer risk and suggests pharmacological targeting of
 insulinemic and hormonal traits as a potential strategy for the prevention of endometrial cancer.

67 Introduction

Endometrial cancer is the most common gynaecological cancer in high-income countries and the second most common globally [1, 2]. In 2020, there were 417,367 new cases diagnosed and 97,370 endometrial cancer-related deaths worldwide [3]. In contrast to several other cancer types where incidence rates have been declining over the past two decades, the global incidence of endometrial cancer continues to increase [4-8].

73 Elevated body mass index (BMI) is an established risk factor for endometrial cancer and is estimated to confer a larger effect on risk of this malignancy than any other cancer type [9-11]. A recent 74 meta-analysis of 30 prospective studies reported that each 5 kg/m² increase in BMI was associated with 75 76 a 54% (95% CI: 47 to 61%) higher risk of endometrial cancer [12-14]. It is estimated that excess adiposity accounts for 34% of global endometrial cancer cases, with the increasing incidence of endometrial 77 cancer mirroring rising levels of obesity worldwide [15-17]. Lifestyle and dietary interventions 78 encouraging maintenance of a healthy weight therefore remain cornerstones for the primary prevention 79 of endometrial cancer [9]. Alongside weight management strategies, greater characterisation of the 80 molecular mechanisms underpinning an effect of excess adiposity on endometrial cancer could provide 81 a complementary approach to cancer prevention through the development of pharmacological 82 interventions targeting these traits in high-risk groups. 83

Observational epidemiological studies have reported associations between several hormonal, metabolic, and inflammatory factors linked to obesity and endometrial cancer, including bioavailable testosterone, sex hormone-binding globulin (SHBG), oestradiol and fasting insulin [18-22]. However, conventional observational studies are susceptible to residual confounding (due to unmeasured or imprecisely measured confounders), reverse causation, and other forms of bias which undermine robust

causal inference. Therefore, the causal nature of these risk factors, and thus their suitability as effective
 intervention targets for endometrial cancer prevention, remains unclear.

Mendelian randomization (MR) is an analytical approach that uses germline genetic variants as 91 92 instruments ("proxies") for risk factors to evaluate the causal effects of these factors on disease 93 outcomes in observational settings [23, 24]. Since germline genetic variants are randomly assorted at meiosis, MR analyses should be less prone to confounding by lifestyle and environmental factors than 94 conventional observational studies. Furthermore, since germline genetic variants are fixed at 95 conception, MR analyses are not subject to reverse causation bias. The statistical power and precision of 96 MR analysis can be increased by employing a "two-sample MR" framework in which summary genetic 97 98 association data from two independent samples – one representing genetic variant-exposure associations and one representing genetic variant-outcome associations - are synthesised to estimate 99 causal effects [25]. 100

Recent MR studies have suggested potential causal relationships between circulating levels of 101 several molecular traits, including low-density lipoprotein (LDL) cholesterol, insulin, total and 102 bioavailable testosterone, and sex hormone-binding globulin (SHBG) and endometrial cancer risk, and 103 have confirmed a causal role of BMI in endometrial cancer risk [17, 26-32]. However, many previously 104 reported molecular risk factors for endometrial cancer from conventional observational studies remain 105 untested in an MR framework, meaning the causal relevance of these factors in disease onset is unclear. 106 Additionally, no MR studies to date have attempted to quantify the potential mediating role of these 107 factors in the relationship between BMI and endometrial cancer risk. 108

Given the unclear causal relevance of previously reported molecular traits in endometrial cancer aetiology, we used a two-sample MR approach to evaluate the causal role of 14 endogenous sex hormones, metabolic traits, and inflammatory markers in endometrial cancer risk (overall and in

- endometrioid and non-endometrioid subtypes). We then used multivariable MR to evaluate and
- quantify the mediating role of these molecular traits in the relationship between BMI and endometrial
- 115 cancer risk.

116 Methods

Our analytical strategy was as follows: first, we attempted to corroborate previous MR findings 117 that there was evidence of a causal relationship between BMI and endometrial cancer risk (overall and 118 119 by histological subtype); second, we examined evidence for a causal relationship between previously 120 reported molecular factors and endometrial cancer risk (overall and by histological subtype); third, we evaluated the causal relationship between BMI and those molecular risk factors that were confirmed to 121 influence endometrial cancer risk (overall and by histological subtype); finally, we performed a 122 mediation analysis to quantify the proportion of the total effect of BMI on endometrial cancer risk that 123 was mediated by each identified trait. 124

125

126 Endometrial cancer study population

Summary genetic association data on overall and subtype-specific endometrial cancer risk were 127 128 obtained from a genome-wide association study (GWAS) of 12,906 cases (including 8,758 endometrioid and 1,230 non-endometrioid endometrial cancer cases) and up to 108,979 controls of European 129 ancestry [31]. This meta-GWAS combined 17 previously reported studies from the Endometrial Cancer 130 Association Consortium (ECAC), the Epidemiology of Endometrial Cancer Consortium (E2C2), and UK 131 Biobank, with four studies contributing samples to more than one genotyping project. Participants were 132 recruited from Australia, Belgium, Germany, Poland, Sweden, the UK, and the USA and associations 133 were adjusted for principal components of ancestry. Genotyping was performed using one of several 134 135 Illumina arrays and imputation was performed using the 1000 Genomes Phase 3 reference panel [33]. 136 Further information on this meta-GWAS including study-specific genotyping, imputation, and quality 137 control procedures is provided in S2 Appendix.

139 Identification of previously reported molecular risk factors for endometrial cancer

We performed two pragmatic searches of the literature using PubMed. The first search 140 identified previously published MR analyses of molecular risk factors for endometrial cancer. The second 141 search identified narrative or systematic reviews of potential molecular mechanisms underpinning the 142 relationship between obesity and endometrial cancer (additional information on search strategies used 143 in literature reviews is presented in S3 Appendix). Combined, these literature reviews identified 20 144 unique molecular traits which could mediate the effect of BMI on endometrial cancer risk, of which 14 145 146 had suitable genetic instruments available. These traits include nine metabolic factors (low-density 147 lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, total serum cholesterol, triglycerides, blood glucose, fasting insulin, insulin-like growth factor 1 (IGF-1), adiponectin, and leptin); 148 149 three endogenous sex hormones or traits that regulate their bioactivity (total and bioavailable testosterone, and SHBG); and two inflammatory markers (interleukin-6 (IL-6) and C-reactive protein 150 (CRP), measured as high-sensitivity CRP) (Fig 1) [29, 34-41]. Summary genetic association data on BMI 151 were obtained from a GWAS of 681,275 individuals of European ancestry [42]. Additional information on 152 participant demographics and covariates included in adjustment strategies across each GWAS are 153 presented in S4 Table. All studies contributing data to these analyses had the relevant institutional 154 review board approval from each country, in accordance with the Declaration of Helsinki, and all 155 participants provided informed consent. 156

157

158 Statistical analyses

MR analysis can generate unbiased estimates of causal effects of risk factors on disease outcomes if the following assumptions are met: (i) the instrument strongly associates with the exposure ("relevance"), (ii) there is no confounding of the instrument-outcome relationship ("exchangeability"), and (iii) the instrument only affects the outcome through the exposure ("exclusion restriction") (**Fig. 2**) [43].

To construct genetic instruments for BMI and previously reported molecular risk factors, we 164 obtained single-nucleotide polymorphisms (SNPs) reliably ($P < 5 \times 10^{-8}$) and independently ($r^2 < 0.001$) 165 associated with each trait. To construct a genetic instrument for leptin, we restricted genetic variants to 166 cis-acting SNPs (i.e. in or within ±100kb from the gene encoding the protein). For leptin, IL-6 and CRP 167 analyses, SNPs were permitted to be in weak linkage disequilibrium (LD) ($r^2 < 0.10$) to maximise 168 instrument strength. For all traits where instruments consisted of SNPs in weak LD (i.e. leptin, IL-6 and 169 CRP), standard errors for causal estimates were inflated to account for correlation between SNPs with 170 reference to the 1000 Genomes Phase 3 reference panel [33, 44]. 171

For traits instrumented by a single SNP, the Wald ratio was used to generate effect estimates and the delta method was used to approximate standard errors [45]. For traits instrumented by two or more SNPs, inverse-variance weighted (IVW) random-effects models were used to estimate causal effects [45]. A Bonferroni correction was applied as a heuristic to account for multiple testing in MR analyses for the 15 risk factors (14 molecular traits and BMI) investigated. Results below this threshold were classified as "strong evidence" ($P < 3.33 \times 10^{-3}$ (0.05/15 traits)), whereas results between this threshold and P < 0.05 were classified as "suggestive evidence".

When using genetic instruments, there is potential for horizontal pleiotropy - when a genetic variant influences an outcome through a biological pathway independent to the exposure, a violation of the "exclusion restriction" criterion [46]. We evaluated the presence of horizontal pleiotropy by

performing various sensitivity analyses. First, for instruments consisting of \geq 10 SNPs, we re-calculated 182 causal estimates obtained from IVW models using MR-Egger regression, weighted median estimation, 183 and weighted mode estimation (additional information on these sensitivity analyses is provided in S2 184 Appendix) [46-48]. Each of these models makes different assumptions regarding the nature of 185 horizontal pleiotropy in the genetic instrument and therefore performing all three can provide 186 187 complementary support to IVW models in evaluating the presence of horizontal pleiotropy. These models were not employed when instruments consisted of < 10 SNPs because of their reduced statistical 188 power to detect horizontal pleiotropy in these settings (additional information on these sensitivity 189 analyses is provided in S2 Appendix). Second, we performed "leave-one-out" analyses for all findings 190 showing strong or suggestive evidence of effects in IVW models (P < 0.05) for traits where instruments 191 consisted of \geq 10 SNPs and findings were consistent across MR-Egger, weighted median, and weighted 192 193 mode sensitivity analyses or where instruments consisted of < 10 SNPs. This approach sequentially removes each SNP from an instrument and then re-calculates the overall effect estimate to examine 194 robustness of findings to individual influential SNPs in IVW models. 195

Instruments were derived from sex-combined GWAS for all traits other than those related to 196 endogenous sex hormones to maximise statistical power where there was limited evidence of sex-197 198 specificity of SNP associations. As a sensitivity analysis we also re-performed MR analyses using sexspecific instruments where possible. For BMI, all analyses with strong or suggestive evidence for an 199 effect (P < 0.05) were repeated using genome-wide significant ($P < 5.0 \times 10^{-8}$) variants identified in 200 female-specific analyses. Likewise, for fasting insulin and CRP analyses, the effect estimates and 201 202 standard errors of SNPs used to instrument these traits were replaced with female-specific values where there was previous evidence of sex-specificity of associations (trait-specific criteria for identifying sex-203 204 specific effects are presented in S2 Appendix). Findings from sex-specific sensitivity analyses are presented in Tables S8, S17, S28-29. Finally, Steiger filtering was performed across all analyses to 205

identify and subsequently remove any SNPs which explained more variance in the outcome than the
 exposure (i.e. suggesting misspecification of the causal direction between traits) [49].

208

209 Mediation analysis

For all molecular traits that were identified as being on the causal pathway between BMI and 210 endometrial cancer risk, we used multivariable MR to generate estimates of the direct effect (i.e. the 211 remaining effect of the exposure on the outcome when the effect of the candidate mediator on the 212 213 outcome has been adjusted for) and indirect effect (i.e. the effect of the exposure on the outcome through the candidate mediator) using the product of coefficients method [50]. The proportion of the 214 total effect of BMI on endometrial cancer risk ("proportion mediated") that was mediated by each 215 molecular trait was calculated using these estimates. In the case of fasting insulin, due to weak 216 217 instrument bias, several different approaches were employed to attempt to maximise conditional 218 instrument strength (for further information on these analyses see S2 Appendix). Standard errors for the proportion mediated were calculated using the delta method [51]. In addition, we aimed to perform 219 additional mediation analyses combining all mediators into a single model to examine the extent to 220 which these mediators influenced endometrial cancer independently or via shared biological pathways 221 (presumed relationships between BMI, fasting insulin, SHBG, bioavailable testosterone, and endometrial 222 cancer risk are presented in Fig 3). When all putative mediators were combined into a single model with 223 BMI, however, there was persistent weak instrument bias. Of various alternate approaches examined to 224 225 minimise this bias, the restriction of models to pairs of mediators (without inclusion of BMI) was found to generate the largest conditional F-statistics for each mediator included in the model (for further 226 information on these analyses see S2 Appendix). 227

229 Sample overlap sensitivity analyses

There was moderate sample overlap (52.2-62.4%) across some analyses which can bias MR 230 estimates toward the confounded observational estimate in the presence of weak instrument bias [52] 231 (S5 Table). This bias can be inflated by "Winner's curse", in which weights for genetic instruments are 232 derived from discovery samples that overlap with outcome samples. Though instruments in this analysis 233 were constructed from genome-wide significant variants ($P < 5.0 \times 10^{-8}$) which should minimise the 234 possibility of weak instrument bias, we performed the following sensitivity analyses to evaluate whether 235 236 our findings could be influenced by sample overlap: i) for analyses examining the effect of blood glucose on endometrial cancer risk, we re-performed MR analyses using alternate GWAS data for this trait 237 where there was no sample overlap [53, 54]; ii) for analyses examining the effect of BMI on total 238 testosterone, bioavailable testosterone, SHBG and endometrial cancer, we re-performed MR analyses 239 using alternate GWAS data for BMI where there was no sample overlap [55]; and iii) for analyses 240 examining the effect of total testosterone, bioavailable testosterone, SHBG and IGF-1 on endometrial 241 cancer (where suitable alternate GWAS data were not available), we re-constructed instruments for sex 242 hormones using more conservative *P*-value thresholds ($P < 5.0 \times 10^{-9}$, $P < 5.0 \times 10^{-10}$) to minimise the 243 potential for inclusion of weak instruments into analyses and then re-performed MR analyses. Similarly, 244 in mediation analysis, due to the presence of sample overlap and possible influence of Winner's curse, 245 for any trait with sample overlap in the same multivariable MR model the analysis was repeated with a 246 more stringent *P* value ($P < 5.0 \times 10^{-9}$) used for instrument construction. 247

All statistical analyses were performed using R (Vienna, Austria) version 4.0.2. Additional information on statistical packages used across various analyses is presented in **S2 Appendix**.

250 Results

251 Evaluating the effect of BMI on endometrial cancer risk

252	In MR analyses, there was strong evidence for an effect of BMI on risk of overall endometrial
253	cancer (odds ratio (OR) per SD (4.7 kg/m ²) increase in BMI: 1.88, 95% confidence interval (CI): 1.69 to
254	2.09, $P = 3.87 \times 10^{-31}$) (Fig 4 , Table 2). This finding was consistent across sensitivity analyses examining
255	evidence of horizontal pleiotropy, including MR-Egger, weighted median, and weighted mode models, in
256	analyses using a female-specific BMI instrument, in analyses exploring potential Winner's curse bias in
257	instrument construction, and in the leave-one-out analysis (S7 Figure, S8 Table, S9 Table).
258	In subtype-stratified analyses, there was evidence to support an effect of BMI on risk of both
259	endometrioid (OR per SD (4.7 kg/m²) increase in BMI: 1.89, 95% CI: 1.65 to 2.16, <i>P</i> = 1.67 x 10 ⁻²⁰) and
260	non-endometrioid endometrial cancer (OR per SD (4.7 kg/m ²) increase in BMI: 1.67, 95% CI: 1.19 to 2.35,
261	$P = 3.03 \times 10^{-3}$) (Fig 4, Table 2). These findings were robust to sensitivity analyses for endometrioid
262	endometrial cancer; however, findings were less consistent for non-endometrioid endometrial cancer in
263	sensitivity analyses using female-specific BMI instruments (S10-11 Figure, S8-9 Table). Therefore, only
264	overall and endometrioid endometrial cancer were included in follow-up analyses.
265	
266	Evaluating the effect of previously reported molecular risk factors on endometrial cancer risk
267	When examining the effect of previously reported molecular risk factors on overall endometrial
268	cancer risk, there was strong evidence for an effect of total testosterone (OR per increase in inverse-
269	normal transformed (INT) nmol/L total testosterone: 1.64, 95% CI: 1.43 to 1.88, $P = 1.71 \times 10^{-12}$),
270	bioavailable testosterone (OR per increase in INT nmol/L bioavailable testosterone: 1.46, 95% CI: 1.29 to
271	1.65, $P = 3.48 \times 10^{-9}$), fasting insulin (OR per increase in natural log transformed pmol/L fasting insulin

3.93, 95% CI: 2.29 to 6.74, $P = 7.18 \times 10^{-7}$), and SHBG (OR per increase in INT nmol/L SHBG 0.71, 95% CI: 0.59 to 0.85, $P = 2.07 \times 10^{-4}$) on endometrial cancer risk (**Fig 5; Table 3**). In addition, there was suggestive evidence for an effect of total serum cholesterol (OR per increase in SD (41.7 mg/dL) total serum cholesterol 0.90, 95% CI: 0.81 to 1.00, $P = 4.01 \times 10^{-2}$) on overall endometrial cancer risk. These findings were consistent across sensitivity analyses (**S12-S16 Figure, S17 Table, S8-S9 Table**).

In subtype-stratified analyses, there was strong evidence to support an effect of total testosterone (OR per increase in INT nmol/L total testosterone: 1.60, 95% CI: 1.36 to 1.87, $P = 8.70 \times 10^{-9}$ 9), bioavailable testosterone (OR per increase in INT nmol/L bioavailable testosterone: 1.46, 95% CI: 1.29 to 1.65, $P = 3.48 \times 10^{-9}$), fasting insulin (OR per increase in natural log transformed pmol/L fasting insulin: 4.64, 95% CI: 2.30 to 9.36, $P = 1.84 \times 10^{-5}$), and SHBG (OR per increase in INT nmol/L SHBG: 0.65, 95% CI: 0.54 to 0.80, $P = 3.31 \times 10^{-5}$) on endometrioid endometrial cancer risk (**Fig 5; Table 3**). Findings were consistent across all sensitivity analyses (**S19-S22 Figure, S9 Table, S17 Table**).

284

285 Evaluating the effect of BMI on previously reported molecular risk factors

When examining the effect of BMI on molecular traits confirmed to have a causal effect on 286 endometrial cancer (either overall or endometrioid subtype), there was evidence for an effect of BMI on 287 fasting insulin (change in natural log transformed fasting insulin: 0.17, 95% CI: 0.15 to 0.19, P = 1.51 x 10⁻ 288 ⁷⁴), SHBG (change in INT SHBG: -0.17, 95% CI: -0.19 to -0.16, $P = 4.86 \times 10^{-125}$), bioavailable testosterone 289 (change in INT bioavailable testosterone: 0.26, 95% CI: 0.23 to 0.29, $P = 9.97 \times 10^{-68}$), total testosterone 290 (change in INT total testosterone: 0.08, 95% CI: 0.05 to 0.11, $P = 9.04 \times 10^{-10}$), and CRP (change in In-291 transformed CRP: 0.35, 95% CI: 0.32 to 0.38, $P = 2.67 \times 10^{-127}$) (Fig 6; Table 4). The direction of effect in 292 MR analyses examining the effect of BMI on total testosterone was inconsistent when employing a 293 weighted mode model, suggesting the potential presence of horizontal pleiotropy. Although there was 294

little evidence for a causal effect of BMI on total serum cholesterol in the IVW model, there was some
evidence for an effect across all three MR sensitivity analysis models, suggesting that horizontal
pleiotropy may be biasing the IVW estimate towards the null. All other findings were consistent across
the various sensitivity analyses (S23-S27 Figure, S8 Table, S17-S18 Table).

299

300 Mendelian randomization mediation analysis

In mediation analyses evaluating the potential mediating role of molecular traits previously 301 302 shown to be on the causal pathway between BMI and endometrial cancer, there was evidence for a mediating role of bioavailable testosterone (15% mediated, 95% CI: 10 to 20%, $P = 1.43 \times 10^{-8}$), fasting 303 insulin (11% of total effect mediated, 95% CI: 1 to 21%, $P = 2.89 \times 10^{-2}$), and SHBG (7% mediated, 95% CI: 304 1 to 12%, $P = 1.81 \times 10^{-2}$) in the relationship between BMI and overall endometrial cancer risk (**Table 5**). 305 There was also evidence for a mediating role of bioavailable testosterone (15% mediated, 95% CI: 9 to 306 22%, $P = 2.15 \times 10^{-6}$) and fasting insulin (16% mediated, 95% CI: 1 to 21%, $P = 2.89 \times 10^{-2}$) in the 307 308 relationship between BMI and endometrioid endometrial cancer risk (Table 5). Although there was little evidence for a mediating role of SHBG in the relationship between sex-combined BMI and endometrioid 309 endometrial cancer (2% mediated, 95% CI: -9 to 14%, $P = 6.87 \times 10^{-1}$), in the female-specific BMI 310 sensitivity analysis there was strong evidence for a mediating role of female-specific SHBG in the 311 relationship between BMI and endometrioid endometrial cancer (8% mediated, 95% CI: 3 to 13%, P = 312 3.38 x 10⁻³). Other than this, findings were consistent across sex-specific BMI, fasting insulin and CRP 313 314 sensitivity analyses (S28-S29 Table).

The conditional F-statistic for both fasting insulin (F=2) and BMI (F=6) in the multivariable MR performed to evaluate the "proportion mediated" by fasting insulin was < 10, indicating that there may

be weak instrument bias in these analyses (i.e. over- or underestimation of the "proportion mediated" 317 by fasting insulin) [56]. When re-performing the "proportion mediated" analysis for fasting insulin using 318 an alternative approach (i.e. using an alternative fasting insulin instrument with a larger sample size and 319 limiting the number of SNPs included in the BMI instrument to the 100 with the strongest evidence of 320 association using an LD threshold r²<0.001), we found that fasting insulin mediated 19% (95% CI: 5 to 321 34%, $P = 9.17 \times 10^{-3}$) of the relationship between BMI and overall endometrial cancer risk and 21% (95%) 322 CI: 5 to 38%, $P = 1.17 \times 10^{-2}$) of the relationship between BMI and endometrioid endometrial cancer risk 323 (S30 Table). 324

In mediation analyses combining pairs of mediators into a single model, the effect of fasting 325 insulin on overall endometrial cancer risk attenuated (~40% log OR reduction) when SHBG (a presumed 326 downstream mediator of fasting insulin) was included in the model (OR per increase in natural log 327 transformed pmol/L fasting insulin: 2.28, 95% CI: 1.34 to 3.86, $P = 2.85 \times 10^{-3}$). The effect of SHBG on 328 overall endometrial cancer attenuated fully when bioavailable testosterone (a presumed downstream 329 mediator of SHBG) was included in the model (OR per increase in INT nmol/L SHBG: 1.08, 95% CI: 0.86 to 330 1.36, $P = 5.00 \times 10^{-1}$) (S34 Table). The effect of fasting insulin on overall endometrial cancer was strongly 331 attenuated when bioavailable testosterone was included in the model (OR per increase in natural log 332 transformed pmol/L fasting insulin: 1.22, 95% CI: 0.48 to 3.11, $P = 6.78 \times 10^{-1}$), which could reflect 333 mediation of the effect of fasting insulin on endometrial cancer via bioavailable testosterone or the 334 presence of conditionally weak instruments in this model. This could result in over- or underestimation 335 of the proportion of the effect of fasting insulin mediated by bioavailable testosterone. 336

For the endometrioid histological subtype, using the same approach, the effect of fasting insulin on endometrioid endometrial cancer did not markedly change (~14% logOR reduction) when SHBG was included in the model (OR per increase in natural log transformed pmol/L fasting insulin: 3.74, 95% CI:

340	0.74 to 19.01, $P = 1.56 \times 10^{-1}$). However, the effect of SHBG on endometrioid endometrial cancer
341	attenuated fully when bioavailable testosterone was included in the model (OR per increase in INT
342	nmol/L SHBG: 1.16, 95% CI: 0.81 to 1.65, $P = 4.12 \times 10^{-1}$). As with analyses of overall endometrial cancer,
343	when fasting insulin and bioavailable testosterone were combined into a single model, the effect of
344	fasting insulin on endometrioid endometrial cancer attenuated toward the null (OR per increase in
345	natural log transformed pmol/L fasting insulin: 1.05, 95% CI: 0.36 to 3.03, P = 9.33 x 10^{-1}), potentially
346	reflecting mediation via bioavailable testosterone or persistent weak instrument bias in this model.

347 Discussion

Our systematic Mendelian randomization (MR) analysis of 14 previously reported molecular risk 348 factors and body mass index (BMI) in 12,906 endometrial cancer cases and 108,979 controls provided 349 350 evidence for roles of elevated BMI, fasting insulin, total and bioavailable testosterone, and sex 351 hormone-binding globulin (SHBG) in risk of overall and endometrioid endometrial cancer. In mediation analyses, we found evidence that fasting insulin, bioavailable testosterone concentrations, and SHBG 352 partially mediated the effect of BMI on overall endometrial cancer risk. When combining pairs of 353 mediators together into a single model, we found evidence that an effect of fasting insulin on 354 endometrial cancer was partially mediated by SHBG levels and that an effect of SHBG on endometrial 355 356 cancer was largely mediated by bioavailable testosterone levels. An effect of fasting insulin on endometrial cancer risk was also strongly attenuated upon adjustment for bioavailable testosterone 357 levels which could reflect mediation of this effect by bioavailable testosterone or conditionally weak 358 instrument bias for fasting insulin concentrations in this analysis. Our analyses found little evidence that 359 several previously reported molecular risk factors, including several metabolic factors (e.g. LDL-C, HDL-C, 360 IGF-1, adiponectin, leptin) and inflammatory markers (CRP, IL-6), were causally implicated in overall or 361 endometrioid endometrial cancer risk. 362

Several of the findings in this analysis are consistent with evidence from prior conventional observational and MR analyses. For example, the effect of BMI on endometrial cancer risk and the stronger evidence of an effect on endometrioid, as compared to non-endometrioid, endometrial cancer is well-established in the literature and has been shown previously in an MR analysis that used an alternative strategy for instrument construction. Our findings supporting a causal effect of BMI on endometrial cancer risk (OR 1.88, 95% CI: 1.69 to 2.09 per SD (4.7 kg/m²) increase) are larger in magnitude than those from pooled analyses of conventional observational analyses (e.g. the World

Cancer Research Fund (WCRF) pooled analysis of 26 prospective studies: RR 1.50, 95% Cl 1.42 to 1.59 per 5.0 kg/m² increase), consistent with previous comparisons of observational and MR estimates across other cancer sites [57, 58]. Smaller magnitudes of effect in observational analyses may reflect regression dilution bias from single time-point measurements of BMI and/or reverse causation from cancerinduced weight loss, whereas MR estimates reflect accumulated exposure across the life-course and are unlikely to be influenced by reverse causation [59].

In agreement with previous MR analyses, our results suggest a causal role of fasting insulin, total 376 and bioavailable testosterone, and SHBG in endometrial cancer risk, although these previous reports 377 either employed smaller sample sizes than this analysis (e.g. fasting insulin analyses were performed in 378 379 1,287 endometrial cancer cases vs 12,906 cases in our analysis) or used somewhat differing methods to examine instrumental variable assumptions [28-30]. The restriction of an effect of BMI to bioavailable 380 (and not total) testosterone is in agreement with previous observational studies which have suggested 381 that BMI influences testosterone levels through decreased production of SHBG rather than a direct 382 effect on testosterone production [60-64]. Additionally, important mediating roles of fasting insulin, 383 bioavailable testosterone, and SHBG in the relationship between BMI and endometrial cancer are 384 consistent with studies of bariatric surgery which have suggested protective effects of this procedure 385 386 against endometrial cancer risk, along with reductions in insulin and bioavailable testosterone levels, and increases in SHBG levels [65-73]. Our findings supporting a role of BMI on these traits are also 387 consistent with the important endocrine function of adipose tissue, which is involved in sex steroid 388 metabolism [62, 74-79]. 389

Potential aetiological roles of the molecular mediators identified in this analysis are consistent with the "unopposed oestrogen" hypothesis which postulates that endometrial carcinogenesis is driven by excess endogenous or exogenous oestrogen levels that are unopposed by progesterone [80-82]. We

UOB Open

were unable to incorporate oestrogen into this analysis as we were unable to identify reliable genetic 393 instruments for this trait. All three of the molecular mediators highlighted in this analysis, however, are 394 known to influence oestrogen: bioavailable testosterone is aromatized to oestradiol; SHBG binds with 395 high-affinity to both oestradiol and bioavailable testosterone [82-87]; and insulin increases androgen 396 and decreases SHBG production [88-91]. We found that an inverse effect of SHBG on endometrial cancer 397 398 risk was largely attenuated upon adjustment for bioavailable testosterone, suggesting a protective effect of SHBG may be driven via binding of biologically active fractions of circulating testosterone. The 399 attenuation of an effect of fasting insulin on endometrial cancer upon adjustment for bioavailable 400 testosterone could reflect mediation of this effect or the presence of conditionally weak instrument bias 401 in this model. In support of the latter explanation, there is biological evidence that hyperinsulinemia and 402 insulin resistance influence endometrial cancer via oestrogen-independent pathways. For example, 403 404 insulin has been shown to bind directly to endometrial cells and promote proliferation, and can activate two pathways known to have an important role in carcinogenesis – the phosphatidylinositol-3-kinase-405 protein kinase B/Akt (PI3K-PKB/Akt) and Ras/Raf/mitogen-activated protein kinase (Ras/Raf/MAPK) 406 pathways [91-96]. 407

Some findings from this MR analysis are not in agreement with evidence from previous 408 conventional observational studies. For example, our analyses found little evidence to support causal 409 roles of several metabolic traits (e.g. circulating HDL-cholesterol, triglycerides, adiponectin, leptin) and 410 inflammatory markers (CRP, IL-6) in endometrial cancer risk, despite these traits being linked to 411 endometrial cancer risk in conventional observational analyses [18-22]. Several of these traits (e.g. HDL-412 413 cholesterol, LDL-cholesterol, triglycerides) represent highly correlated metabolic perturbations associated with the obese phenotype which may be too clustered to disentangle using conventional 414 multivariable regression methods [97]. Consequently, some of the divergence in findings across previous 415 conventional observational studies and this MR analysis could reflect residual confounding in the 416

former. Another potential explanation for divergence in findings is the susceptibility of conventional
observational studies to reverse causation (i.e., latent, undiagnosed endometrial cancer influencing
levels of a presumed exposure). For example, a previously reported association of circulating IL-6
concentrations with endometrial cancer risk could reflect IL-6 secretion by endometrial cancerassociated fibroblasts rather than a role of IL-6 in endometrial cancer development [98, 99].

We were unable to replicate a previously reported MR-based inverse association of LDL 422 cholesterol levels and endometrial cancer risk in the Endometrial Cancer Association Consortium (IVW 423 OR per SD increase in LDL cholesterol: 0.90, 95% CI: 0.85 to 0.95, $P = 8.39 \times 10^{-5}$). In the previous 424 analysis, SNPs were permitted to be in weak linkage disequilibrium (LD) (pairwise correlation $r^2 < 0.05$ vs 425 $r^2 < 0.001$ in our analysis) and a Heterogeneity in Dependent Instruments (HEIDI) test was performed to 426 identify potentially pleiotropic SNPs, resulting in the removal of 6 such SNPs from the 146 SNPs initially 427 used as an instrument. We attempted to replicate these previously reported findings using a more 428 stringent r^2 threshold (i.e. r^2 <0.001) followed by use of the HEIDI test (resulting in the removal of 2 429 potentially pleiotropic SNPs) which resulted in a causal estimate that was closer in magnitude to that 430 previously reported (IVW OR 0.93, 95% CI: 0.86 to 1.00, $P = 4.10 \times 10^{-2}$) (**S45 Table**). However, there was 431 greater imprecision in our estimate compared to this previous analysis which could reflect the more 432 433 liberal LD threshold employed in this earlier analysis.

Our MR analysis provides key insights into potential molecular pathways linking excess adiposity to endometrial cancer risk. This analysis has several strengths including the use of a systematic approach to collate previously reported molecular risk factors for endometrial cancer; the appraisal of their causal relevance in overall and endometrioid endometrial cancer aetiology using an MR framework which should be less prone to conventional issues of confounding and cannot be influenced by reverse causation; the employment of several complementary sensitivity analyses to rigorously assess for

violations of MR assumptions; and the use of a summary data-based MR approach which permitted us
 to leverage large-scale GWAS data from several studies, enhancing statistical power and precision of
 causal estimates.

443 There are several limitations to our analysis. First, we were unable to evaluate the role of six previously reported molecular risk factors for endometrial cancer due to the absence of reliable genetic 444 instruments for these traits. These six risk factors included oestradiol which is believed to be an 445 important molecular mediator of the effect of BMI on endometrial cancer risk[9]. Second, some of the 446 effect estimates for SNPs included in genetic instruments were obtained from discovery GWAS and have 447 not been replicated in an independent sample which can result in "Winner's curse" bias. There was 448 449 sample overlap in this analysis across certain traits; however, the use of conventionally strong (P < 5.0 x 10^{-8}) instruments for these traits and the consistency of most findings in sensitivity analyses examining 450 their robustness to potential Winner's curse bias suggests that this phenomenon was unlikely to 451 markedly influence the results presented in this analysis. Third, although sex-specific sensitivity analyses 452 were performed where data were available, some prior GWAS used in this analysis did not examine for 453 454 heterogeneity of SNP effects by sex which prevented evaluation of the effect of certain traits on endometrial cancer risk using sex-specific instruments. Fourth, univariable and multivariable MR 455 456 analyses presented here assume that relationships between exposures and outcomes are linear, although it has been previously suggested that the relationship between BMI and endometrial cancer 457 may best be explained by a non-linear model [12, 100]. Fifth, our analysis was almost exclusively 458 restricted to individuals of European ancestry to minimise bias from population stratification, which may 459 limit the generalisability of our findings to non-European populations. Finally, while various sensitivity 460 analyses were performed to examine violations of exchangeability and exclusion restriction criteria, 461 these assumptions are unverifiable. 462

With the global incidence of overweight and obesity projected to increase and challenges in 463 implementing successful weight loss strategies, pharmacological approaches targeting molecular 464 mediators of the effect of obesity on endometrial cancer development may offer a viable approach for 465 cancer prevention in high-risk groups [101-105]. Metformin, a safe and inexpensive first-line treatment 466 for type 2 diabetes, could serve as a promising chemoprevention agent for endometrial cancer as it 467 468 increases insulin sensitivity, thus reversing insulin resistance and lowering fasting insulin levels, 469 alongside inhibiting endometrial proliferation [9, 106]. In addition, unlike some other oral hypoglycaemic medications, metformin users show a tendency toward sustained weight loss [107]. 470 Bioavailable testosterone and SHBG also present potential pharmacological targets, though the 471 multifaceted function of these hormones means that targeting these traits may result in adverse effects 472 [108-113]. Phase II clinical trials examining the efficacy of a combination of contraceptive intrauterine 473 474 devices, metformin, and weight loss interventions as a non-invasive treatment option for individuals with obesity with early-stage endometrial cancer have had encouraging results, and weight loss has 475 been shown to improve oncological outcomes in women with endometrial cancer undergoing progestin 476 treatment [114, 115]. 477

Our systematic evaluation of 14 previously reported candidate mediators of the effect of BMI on 478 479 endometrial cancer risk identifies fasting insulin, bioavailable testosterone, and SHBG as plausible mediators of this relationship. While we were unable to entirely disentangle the independent effects of 480 these three traits, identification of a potential mediating role of these traits (and, in particular, fasting 481 insulin) in endometrial carcinogenesis is nonetheless informative for the development of 482 483 pharmacological interventions targeting these traits for cancer prevention. In this respect, future assessment of the effect of drugs which target molecular mediators identified in this analysis using a 484 "drug-target Mendelian randomization" approach could inform on the potential efficacy of the 485 repurposing of medications for endometrial cancer prevention. 486

487 Conclusion

Our comprehensive Mendelian randomization analysis provides insight into potential causal mechanisms linking excess adiposity to endometrial cancer risk. We show that lifelong cumulative elevated BMI causes a larger increased risk than that reported in previous conventional observational studies. We found strong evidence for a mediating role of fasting insulin, bioavailable testosterone and SHBG in the effect of BMI on endometrial cancer risk. These results suggest pharmacological targeting of insulin-related and hormonal traits as a potential strategy for the prevention of endometrial cancer. 494 Funding

495 EH is supported by a Cancer Research UK Population Research Committee Studentship

496 (C18281/A30905). EH, VT, GDS, RMM, KR and JY are supported by Cancer Research UK (C18281/A29019)

497 programme grant (the Integrative Cancer Epidemiology Programme). EH, ES, VT, GDS, RMM, and JY are

498 part of the Medical Research Council Integrative Epidemiology Unit at the University of Bristol which is

supported by the Medical Research Council (MC_UU_00011/1, MC_UU_00011/3, MC_UU_00011/6, and

500 MC_UU_00011/4) and the University of Bristol. JY is supported by a Cancer Research UK Population

Research Postdoctoral Fellowship (C68933/A28534). RMM is also supported by the NIHR Bristol

502 Biomedical Research Centre which is funded by the NIHR and is a partnership between University

Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. TMF is funded by the

504 MRC (MR/T002239/1). TAO'M is funded by a National Health and Medical Research Council Investigator

505 Fellowship (APP1173170).

Disclaimers: The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care; where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions,

policy, or views of the International Agency for Research on Cancer/World Health Organization.

511

512 Acknowledgements

The endometrial cancer genome-wide association analyses were supported by the National Health and
Medical Research Council of Australia (APP552402, APP1031333, APP1109286, APP1111246 and
APP1061779), the U.S. National Institutes of Health (R01-CA134958), European Research Council (EU
FP7 Grant), Wellcome Trust Centre for Human Genetics (090532/Z/09Z) and Cancer Research UK.
OncoArray genotyping of ECAC cases was performed with the generous assistance of the Ovarian Cancer

Association Consortium (OCAC), which was funded through grants from the U.S. National Institutes of 518 Health (CA1X01HG007491-01 (C.I. Amos), U19-CA148112 (T.A. Sellers), R01-CA149429 (C.M. Phelan) and 519 R01-CA058598 (M.T. Goodman); Canadian Institutes of Health Research (MOP-86727 (L.E. Kelemen)) 520 and the Ovarian Cancer Research Fund (A. Berchuck). We particularly thank the efforts of Cathy Phelan. 521 OncoArray genotyping of the BCAC controls was funded by Genome Canada Grant GPH-129344, NIH 522 523 Grant U19 CA148065, and Cancer UK Grant C1287/A16563. All studies and funders are listed in O'Mara et al (2018). The authors would like to thank the participants of the 1958 British birth cohort (BS58), 524 Academic Medical Centre Amsterdam Premature Arosclerosis Study (AMC-PAS), Age, Gene/Environment 525 Susceptibility (AGES) study, Anglo-Scandinavian Cardiac Outcome Trial (ASCOT), Aro-Express Biobank 526 Study (AE), Arosclerosis Risk in Communities (ARIC) study, Arosclerotic Disease, Vascular Function, and 527 Genetic Epidemiology (ADVANCE) study, Asian Indian Diabetic Heart Study (AIDHS) /Sikh Diabetes Study 528 529 (SDS), Avon Longitudinal Study of Parents and Children (ALSPAC), Baltimore Longitudinal Study of Aging (BLSA), British Genetics of Hypertension (BRIGHT) Study, Busselton Health Study (BSN), C Reactive 530 Protein Coronary Heart Disease Genetics Collaboration (CCGC), Cancer Prostate in Sweden 1 (CAPS1) 531 study, Cancer Prostate in Sweden 2 (CAPS2) study, CardioGenics study, Cardiovascular Health Study 532 (CHS), Cardiovascular Health Study (CHS), Cardiovascular Risk in Young Finns Study (YFS), Carotid Intima 533 Media Thickness (IMT) and IMT-Progression as Predictors of Vascular Events in a High Risk European 534 535 Population (IMPROVE) study, Cebu Longitudinal Health and Nutrition Survey (CLHNS), Charles Bronfman Institute for Personalized Medicine (IPM) BioMe Biobank Program, Cohorte Lausannoise (CoLaus) study, 536 Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Inflammation Working Group 537 (CIWG), CROATIA-Vis study, Croatian Study (CROAS), Danish National Birth Cohort (DNBC), Data from an 538 Epidemiological Study on Insulin Resistance syndrome (DESIR), Diabetes Epidemiology: Collaborative 539 analysis of Diagnostic criteria in Europe (DECODE) study, Diabetes Genetics Initiative (DGI), DiaGen 540 541 consortium, Dose-Responses to Exercise Training (DR's EXTRA) study, Dundee study, Dutch and Belgian

Lung Cancer Screening Trial (NELSON), Echinococcus Multilocularis and Internal Diseases in Leutkirch 542 (EMIL) study, Edinburgh Artery Study (EAS), Efficiency and safety of varying frequency of whole blood 543 donation (INTERVAL) study, Ely Study, Endometrial Cancer Association Consortium (ECAC), Epidemiology 544 of Endometrial Cancer Consortium (E2C2), EpiHealth cohort, Erasmus Rucphen Family (ERF) study, 545 Estonian Biobank, Estonian Genome Center of University of Tartu (EGCUT) study, European Prospective 546 547 Investigation into Cancer and Nutrition (EPIC) study, Family Blood Pressure Program (FBPP), Family Blood Pressure Program (FBPP), Family Heart Study (FamHS), Fast Revascularisation during Instability in 548 Coronary artery disease (FRISCII) study, Fendland study, Finland-United States Investigation of NIDDM 549 Genetics (FUSION) study, FinMetSeq, Finnish Cardiovascular Study (FINCAVAS), Finnish Diabetes 550 Prevention Study (DPS), Finnish Genetic Study of Arrhythmic Events (FinGesture), Finnish National 551 Diabetes Prevention Program (FIN-D2D), Finnish Twin Cohort (FTC), Finnisk study, Framingham Heart 552 553 Study (FRAM), Genetic Investigation of ANthropometric Traits (GIANT), Gene-Lifestyle interactions And Complex traits Involved in Elevated disease Risk Study (GLACIER), Genetic determinants of Obesity and 554 Metabolic syndrome (DILGOM) study, Genetic Epidemiology Network of Arteriopathy (GENOA) study, 555 Genetic Predisposition of Coronary Heart Disease in Patients Verified with Coronary Angiogram 556 (COROGENE), Genetics of Diabetes Audit and Research Study (GoDartS), GenomEUtwin, German 557 Myocard Infarct Family Study I (GerMiFSI), German Myocard Infarct Family Study II (GerMiFSII), Global 558 559 Lipids Consortium (GLGC), Gonburg Osteoporosis and Obesity Determinants Study (GOOD), Health 2000 study, Health and Retirement Study (HRS), Health, Aging, and Body Composition Study (Health ABC), 560 Health, Risk Factors, Training and Genetics (HERITAGE) Family Study, Heinz Nixdorf Recall (HNR), 561 Hellenic study of Interactions between Single nucleotide polymorphisms and Eating in Arosclerosis 562 Susceptibility (THISEAS), Helsinki Birth Cohort Study (HBCS), Heredity and Phenotype Intervention (HAPI) 563 Heart Study, Invecchiare in Chianti (InCHIANTI) study, Kingston Gene-by-environment; subset of 564 565 International Collaborative Study of Hypertension in Blacks (GXE), Kooperative Gesundheitsforschung in

der Region Augsburg (KORA) study, Korcula study, Leiden Longevity Study (LLS), Leipzig adults study, 566 Leipzig kids study, Lifelines cohort, London Life Sciences Prospective Population Study (LOLIPOP), 567 LUdwigshafen RIsk and Cardiovascular Health (LURIC) study, MAGIC (the Meta-Analyses of Glucose and 568 Insulin-related traits Consortium), Malmo Preventive Project-Re-examination (MPP-RES) study, Malmo 569 Diet and Cancer Study (MDC), Medical research Council (MRC) National Survey of Health & Development 570 571 (MRC NSHD), Medical Research Council (MRC) National Survey of Health and Development (NSHD), Medical Research Council/Uganda Virus Research Institute General Population Cohort (MRC/UVRIGPC), 572 Metabolic Syndrome in Men (METSIM) study, Microisolates in South Tyrol Study (MICROS), Molecular 573 Genetics of Schizophrenia (MGS), MOnica Risk, Genetics, Archiving and Monograph (MORGAM), 574 Multiethnic Cohort Study (MEC), Myocardial Infarction Genetics Consortium (Migen), Nerlands Study of 575 Depression and Anxiety (NESDA), Nerlands Twin Register (NTR), Nijmegen Bladder Cancer Study and 576 577 Nijmegen Biomedical Study (RUNMC), Nord- Trøndelag Health Study (HUNT), Northern Finland Birth Cohort 1966 (NFBC66), Northern Finland Birth Cohort 1986 (NFBC86), Northern Sweden Population 578 Health Study (NSPHS), Nurse's Health Study (NHS), Orkney Complex Disease Study (ORCADES), Pakistan 579 Risk of Myocardial Infarction Study (PROMIS), Precocious Coronary Artery Disease (PROCARDIS) study, 580 Prevention of REnal and Vascular ENd-stage Disease (PREVEND) study, Prospective Investigation of 581 Vasculature in Uppsala Seniors (PIVUS) study, PROspective study of Pravastatin in Elderly at Risk for 582 583 vascular disease (PROSPER/PHASE), Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO), Quebec Family Study (QFS), Relationship between Insulin Sensitivity and Cardiovascular disease 584 Study (RISC), Rotterdam study, SardiNIA Project, Seychelles Family Study (TANDEM), Sorbs study, 585 Spanish Town study (SPT), STabilization of Arosclerotic plaque By Initiation of darapLadlb rapY 586 (STABILITY), Stanley cohort, Stockholm Coronary Arosclerosis Risk Factor (SCARF) study, Stockholm Heart 587 Epidemiology Program (SHEEP), Studies of Epidemiology and Risk factors in Cancer Heredity / UK 588 589 Ovarian Cancer Population Study (SEARCH/UKOPS), Study of Health in Pomerania (SHIP), Suivi

Temporaire Annuel Non Invasif de la Santé des Lorrains Assurés Sociaux (STANISLAS) cohort, Swedish 590 And Singapore Breast Association Consortium (SASBAC), Swedish Twin Registry (STR), Taichi Consortium, 591 Tracking Adolescents' Individual Lives Survey (TRAILS), Tromsø Study, Twin study at Queensland Institute 592 of Medical Research (QIMR), Twins UK, UK Biobank, Uppsala Longitudinal Study of Adult Men (ULSAM), 593 Vitamin D and Type 2 Diabetes (D2d) study, Wellcome Trust Case Control Consortium (WTCCC), 594 595 Whitehall study, Women's Genome Health Study (WGHS), and Women's Health Initiative (WHI) for their participation in these studies along with the principal investigators for generating the data utilised for 596 this analysis and for making these data available in the public domain. Data on glycaemic traits have 597 been contributed by MAGIC investigators and have been downloaded from 598

- www.magicinvestigators.org, and data on oestradiol and blood glucose have been contributed by the
- Neale lab and have been downloaded from <u>www.nealelab.is</u>.

604

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 1. 602 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 603 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394-424. doi:

- https://doi.org/10.3322/caac.21492. 605
- Howlader N NA, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, 2. 606

Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-607

2014, National Cancer Institute. Bethesda, MD, https://seercancergov/csr/1975 2014/. Based 608

on November 2016 SEER data submission, posted to the SEER web site, April 2017. 609

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer 3. 610

Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 611

185 Countries. CA Cancer J Clin. 2021;71(3):209-49. Epub 2021/02/05. doi: 10.3322/caac.21660. 612

PubMed PMID: 33538338. 613

4. Sheikh MA, Althouse AD, Freese KE, Soisson S, Edwards RP, Welburn S, et al. USA 614

Endometrial Cancer Projections to 2030: should we be concerned? Future Oncology. 615

2014;10(16):2561-8. doi: 10.2217/fon.14.192. PubMed PMID: 25531045. 616

5. Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International Patterns and Trends in 617

Endometrial Cancer Incidence, 1978–2013. JNCI: Journal of the National Cancer Institute. 618

2017;110(4):354-61. doi: 10.1093/jnci/djx214. 619

6. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: A Cancer Journal for Clinicians. 620

2016;66(1):7-30. doi: https://doi.org/10.3322/caac.21332. 621

7. Zhang S, Gong T-T, Liu F-H, Jiang Y-T, Sun H, Ma X-X, et al. Global, Regional, and National
 Burden of Endometrial Cancer, 1990-2017: Results From the Global Burden of Disease Study,

2017. Front Oncol. 2019;9:1440-. doi: 10.3389/fonc.2019.01440. PubMed PMID: 31921687.

8. Mullins MA, Cote ML. Beyond Obesity: The Rising Incidence and Mortality Rates of

⁶²⁶ Uterine Corpus Cancer. J Clin Oncol. 2019;37(22):1851-3. Epub 2019/06/20. doi:

627 10.1200/JCO.19.01240. PubMed PMID: 31232669.

9. Onstad MA, Schmandt RE, Lu KH. Addressing the Role of Obesity in Endometrial Cancer
Risk, Prevention, and Treatment. J Clin Oncol. 2016;34(35):4225-30. Epub 2016/11/07. doi:
10.1200/JCO.2016.69.4638. PubMed PMID: 27903150.

10. Lega IC, Lipscombe LL. Review: Diabetes, Obesity, and Cancer—Pathophysiology and
 Clinical Implications. Endocrine Reviews. 2019;41(1):33-52. doi: 10.1210/endrev/bnz014.

11. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D, et al. Cancer incidence and

mortality in relation to body mass index in the Million Women Study: cohort study. BMJ.

635 2007;335(7630):1134-. Epub 2007/11/06. doi: 10.1136/bmj.39367.495995.AE. PubMed PMID:

636 **17986716**.

12. Aune D, Navarro Rosenblatt DA, Chan DS, Vingeliene S, Abar L, Vieira AR, et al.

Anthropometric factors and endometrial cancer risk: a systematic review and dose-response

meta-analysis of prospective studies. Ann Oncol. 2015;26(8):1635-48. Epub 2015/03/21. doi:

640 10.1093/annonc/mdv142. PubMed PMID: 25791635.

13. World Cancer Research Fund/American Institute for Cancer Research. Continuous

⁶⁴² Update Project Expert Report 2018. Diet, nutrition, physical activity and ovarian cancer.

643 Available at dietandcancerreport.org.

World Cancer Research Fund/American Institute for Cancer Research. Continuous
Update Project Expert Report 2018. Diet, nutrition, physical activity and oesophageal cancer.
Available at dietandcancerreport.org.

Nevadunsky NS, Van Arsdale A, Strickler HD, Moadel A, Kaur G, Levitt J, et al. Obesity
and age at diagnosis of endometrial cancer. Obstet Gynecol. 2014;124(2 Pt 1):300-6. Epub
2014/07/09. doi: 10.1097/aog.000000000000381. PubMed PMID: 25004350.

16. McCullough ML, Patel AV, Patel R, Rodriguez C, Feigelson HS, Bandera EV, et al. Body

mass and endometrial cancer risk by hormone replacement therapy and cancer subtype.

652 Cancer Epidemiol Biomarkers Prev. 2008;17(1):73-9. Epub 2008/01/12. doi: 10.1158/1055-

653 9965.Epi-07-2567. PubMed PMID: 18187388.

17. Painter JN, O'Mara TA, Marquart L, Webb PM, Attia J, Medland SE, et al. Genetic Risk

655 Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not

656 Waist: Hip Ratio, Is Causal for Endometrial Cancer. Cancer epidemiology, biomarkers &

prevention : a publication of the American Association for Cancer Research, cosponsored by the

American Society of Preventive Oncology. 2016;25(11):1503-10. Epub 2016/08/22. doi:

659 10.1158/1055-9965.EPI-16-0147. PubMed PMID: 27550749.

18. Dossus L, Rinaldi S, Becker S, Lukanova A, Tjonneland A, Olsen A, et al. Obesity,

inflammatory markers, and endometrial cancer risk: a prospective case-control study.

662 Endocrine-Related Cancer. 2010;17(4):1007. doi: 10.1677/erc-10-0053.

19. Friedenreich CM, Langley AR, Speidel TP, Lau DCW, Courneya KS, Csizmadi I, et al. Case-

664 control study of inflammatory markers and the risk of endometrial cancer. European Journal of

Cancer Prevention. 2013;22(4):374-9. doi: 10.1097/CEJ.0b013e32835b3813. PubMed PMID:
00008469-201307000-00013.

Wang T, Rohan TE, Gunter MJ, Xue X, Wactawski-Wende J, Rajpathak SN, et al. A
Prospective Study of Inflammation Markers and Endometrial Cancer Risk in Postmenopausal
Hormone Nonusers. Cancer Epidemiology Biomarkers & amp; Prevention. 2011;20(5):971-7. doi:
10.1158/1055-9965.Epi-10-1222.

21. Lindemann K, Vatten LJ, Ellstrøm-Engh M, Eskild A. Serum lipids and endometrial cancer

risk: Results from the HUNT-II study. International Journal of Cancer. 2009;124(12):2938-41.

673 doi: <u>https://doi.org/10.1002/ijc.24285</u>.

574 22. Swanson CA, Potischman N, Barrett RJ, Berman ML, Mortel R, Twiggs LB, et al.

Endometrial cancer risk in relation to serum lipids and lipoprotein levels. Cancer Epidemiol

676 Biomarkers Prev. 1994;3(7):575-81. Epub 1994/10/01. PubMed PMID: 7827588.

23. Yarmolinsky J, Wade KH, Richmond RC, Langdon RJ, Bull CJ, Tilling KM, et al. Causal

Inference in Cancer Epidemiology: What Is the Role of Mendelian Randomization? Cancer

679 Epidemiology Biomarkers & amp; Prevention. 2018;27(9):995-1010. doi: 10.1158/1055-

680 **9965.Epi-17-1177.**

Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology
contribute to understanding environmental determinants of disease?*. International Journal of
Epidemiology. 2003;32(1):1-22. doi: 10.1093/ije/dyg070.

⁶⁸⁴ 25. Pierce BL, Burgess S. Efficient design for Mendelian randomization studies: subsample

and 2-sample instrumental variable estimators. Am J Epidemiol. 2013;178(7):1177-84. Epub

2013/07/19. doi: 10.1093/aje/kwt084. PubMed PMID: 23863760; PubMed Central PMCID:
PMCPMC3783091.

Thompson DJ, O'Mara TA, Glubb DM, Painter JN, Cheng T, Folkerd E, et al. CYP19A1 fine mapping and Mendelian randomization: estradiol is causal for endometrial cancer. Endocr Relat

⁶⁹⁰ Cancer. 2016;23(2):77-91. Epub 2015/11/18. doi: 10.1530/erc-15-0386. PubMed PMID:

⁶⁹¹ 26574572; PubMed Central PMCID: PMCPMC4697192.

692 27. Kho P-F, Amant F, Annibali D, Ashton K, Attia J, Auer PL, et al. Mendelian randomization

analyses suggest a role for cholesterol in the development of endometrial cancer. International

⁶⁹⁴ Journal of Cancer. 2021;148(2):307-19. doi: <u>https://doi.org/10.1002/ijc.33206</u>.

695 28. Nead KT, Sharp SJ, Thompson DJ, Painter JN, Savage DB, Semple RK, et al. Evidence of a

696 Causal Association Between Insulinemia and Endometrial Cancer: A Mendelian Randomization

697 Analysis. J Natl Cancer Inst. 2015;107(9). Epub 2015/07/03. doi: 10.1093/jnci/djv178. PubMed

698 PMID: 26134033; PubMed Central PMCID: PMCPMC4572886.

699 29. Ruth KS, Day FR, Tyrrell J, Thompson DJ, Wood AR, Mahajan A, et al. Using human

⁷⁰⁰ genetics to understand the disease impacts of testosterone in men and women. Nature

701 Medicine. 2020;26(2):252-+. doi: 10.1038/s41591-020-0751-5. PubMed PMID:

702 WOS:000512529400005.

703 30. Mullee A, Dimou N, Allen N, O'Mara T, Gunter MJ, Murphy N. Testosterone, sex

⁷⁰⁴ hormone-binding globulin, insulin-like growth factor-1 and endometrial cancer risk:

observational and Mendelian randomization analyses. Br J Cancer. 2021;125(9):1308-17. Epub

706 2021/08/08. doi: 10.1038/s41416-021-01518-3. PubMed PMID: 34363033; PubMed Central

707 PMCID: PMCPMC8548546.

709	new susceptibility loci for endometrial cancer. Nat Commun. 2018;9(1):3166. Epub 2018/08/11.
710	doi: 10.1038/s41467-018-05427-7. PubMed PMID: 30093612; PubMed Central PMCID:
711	PMCPMC6085317.
712	32. Dimou NL, Papadimitriou N, Mariosa D, Johansson M, Brennan P, Peters U, et al.
713	Circulating adipokine concentrations and risk of five obesity-related cancers: A Mendelian
714	randomization study. Int J Cancer. 2021;148(7):1625-36. Epub 2020/10/11. doi:
715	10.1002/ijc.33338. PubMed PMID: 33038280; PubMed Central PMCID: PMCPMC7894468.
716	33. Auton A, Abecasis GR, Altshuler DM, Durbin RM, Abecasis GR, Bentley DR, et al. A global
717	reference for human genetic variation. Nature. 2015;526(7571):68-74. doi:
718	10.1038/nature15393.
719	34. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery
720	and refinement of loci associated with lipid levels. Nature Genetics. 2013;45(11):1274-+. doi:
721	10.1038/ng.2797. PubMed PMID: WOS:000326384100007.
722	35. Scott RA, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan JA, et al. Large-scale
723	association analyses identify new loci influencing glycemic traits and provide insight into the
724	underlying biological pathways. Nature Genetics. 2012;44(9):991-+. doi: 10.1038/ng.2385.
725	PubMed PMID: WOS:000308491200010.

O'Mara TA, Glubb DM, Amant F, Annibali D, Ashton K, Attia J, et al. Identification of nine

36. Neale B. GWAS results. UK Biobank website. [updated 1st August 2018; cited 2020
9/12/20].

31.

Sinnott-Armstrong N, Tanigawa Y, Amar D, Mars NJ, Aguirre M, Venkataraman GR, et al. 37. 728 Genetics of 38 blood and urine biomarkers in the UK Biobank. bioRxiv. 2019:660506. doi: 729 10.1101/660506. 730

38. Georgakis MK, Malik R, Gill D, Franceschini N, Sudlow CLM, Dichgans M. Interleukin-6 731 signaling effects on ischemic stroke and other cardiovascular outcomes: a Mendelian 732 Randomization study. medRxiv. 2019:19007682. doi: 10.1101/19007682. 733

39. Dastani Z, Hivert M-F, Timpson N, Perry JRB, Yuan X, Scott RA, et al. Novel Loci for 734 Adiponectin Levels and Their Influence on Type 2 Diabetes and Metabolic Traits: A Multi-Ethnic 735 Meta-Analysis of 45,891 Individuals. PLOS Genetics. 2012;8(3):e1002607. doi:

10.1371/journal.pgen.1002607. 737

Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al. Genomic atlas of 738 40.

the human plasma proteome. Nature. 2018;558(7708):73-9. doi: 10.1038/s41586-018-0175-2. 739

41. Ligthart S, Vaez A, Võsa U, Stathopoulou MG, de Vries PS, Prins BP, et al. Genome 740

Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight 741

Pathways that Link Inflammation and Complex Disorders. Am J Hum Genet. 2018;103(5):691-742

706. Epub 2018/11/06. doi: 10.1016/j.ajhg.2018.09.009. PubMed PMID: 30388399; PubMed 743

Central PMCID: PMC6218410. 744

42. Yengo L, Sidorenko J, Kemper KE, Zheng Z, Wood AR, Weedon MN, et al. Meta-analysis 745

of genome-wide association studies for height and body mass index in \sim 700000 individuals of 746

European ancestry. Hum Mol Genet. 2018;27(20):3641-9. Epub 2018/08/21. doi: 747

10.1093/hmg/ddy271. PubMed PMID: 30124842; PubMed Central PMCID: PMCPMC6488973. 748

736

Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a 43. 749 guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601. Epub 2018/07/14. doi: 750 10.1136/bmj.k601. PubMed PMID: 30002074; PubMed Central PMCID: PMCPMC6041728 751 interests and declare that we have no competing interests. 752 44. Burgess S, Zuber V, Valdes-Marquez E, Sun BB, Hopewell JC. Mendelian randomization 753 with fine-mapped genetic data: Choosing from large numbers of correlated instrumental 754 variables. Genetic Epidemiology. 2017;41(8):714-25. doi: https://doi.org/10.1002/gepi.22077. 755 756 45. Hemani G, Bowden J, Davey Smith G. Evaluating the potential role of pleiotropy in Mendelian randomization studies. Hum Mol Genet. 2018;27(R2):R195-r208. Epub 2018/05/18. 757 doi: 10.1093/hmg/ddy163. PubMed PMID: 29771313; PubMed Central PMCID: 758 PMCPMC6061876. 759 46. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian 760 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet 761

⁷⁶² Epidemiol. 2016;40(4):304-14. Epub 2016/04/12. doi: 10.1002/gepi.21965. PubMed PMID:

⁷⁶³ 27061298; PubMed Central PMCID: PMCPMC4849733.

47. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian
randomization via the zero modal pleiotropy assumption. International journal of epidemiology.
2017;46(6):1985-98. doi: 10.1093/ije/dyx102. PubMed PMID: 29040600.

767 48. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments:

refrect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512-

769 25. Epub 2015/06/08. doi: 10.1093/ije/dyv080. PubMed PMID: 26050253; PubMed Central

770 PMCID: PMCPMC4469799.

771	49.	Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between
772	imprec	isely measured traits using GWAS summary data. PLoS Genet. 2017;13(11):e1007081.
773	Epub 2	017/11/18. doi: 10.1371/journal.pgen.1007081. PubMed PMID: 29149188; PubMed
774	Centra	PMCID: PMCPMC5711033.
775	50.	Burgess S, Thompson SG. Multivariable Mendelian Randomization: The Use of
776	Pleiotr	opic Genetic Variants to Estimate Causal Effects. American Journal of Epidemiology.
777	2015;1	81(4):251-60. doi: 10.1093/aje/kwu283.
778	51.	Cheung MWL. Comparison of methods for constructing confidence intervals of
779	standa	rdized indirect effects. Behavior Research Methods. 2009;41(2):425-38. doi:
780	10.375	8/BRM.41.2.425.
781	52.	Haycock PC, Burgess S, Wade KH, Bowden J, Relton C, Davey Smith G. Best (but oft-
782	forgott	en) practices: the design, analysis, and interpretation of Mendelian randomization
783	studies	a. Am J Clin Nutr. 2016;103(4):965-78. doi: 10.3945/ajcn.115.118216. PubMed PMID:
784	269619	927.
785	53.	Kettunen J, Demirkan A, Würtz P, Draisma HH, Haller T, Rawal R, et al. Genome-wide
786	study f	or circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. Nat
787	Comm	un. 2016;7:11122. Epub 2016/03/24. doi: 10.1038/ncomms11122. PubMed PMID:
788	27005	778.
789	54.	Prins BP, Kuchenbaecker KB, Bao Y, Smart M, Zabaneh D, Fatemifar G, et al. Genome-
790	wide a	nalysis of health-related biomarkers in the UK Household Longitudinal Study reveals
791	novel a	ssociations. Sci Rep. 2017;7(1):11008. Epub 2017/09/10. doi: 10.1038/s41598-017-
792	10812-	1. PubMed PMID: 28887542; PubMed Central PMCID: PMCPMC5591265.

55. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Felix R, et al. Genetic studies of body

mass index yield new insights for obesity biology. Nature. 2015;518(7538):197-U401. doi:

⁷⁹⁵ 10.1038/nature14177. PubMed PMID: WOS:000349190300031.

56. Sanderson E, Spiller W, Bowden J. Testing and Correcting for Weak and Pleiotropic

⁷⁹⁷ Instruments in Two-Sample Multivariable Mendelian Randomisation. bioRxiv.

798 2020:2020.04.02.021980. doi: 10.1101/2020.04.02.021980.

799 57. World Cancer Research Fund/American Institute for Cancer Research. Continuous

⁸⁰⁰ Update Project Expert Report 2018. Diet, nutrition, physical activity and endometrial cancer.

801 Available at dietandcancerreport.org.

58. Mariosa D, Carreras-Torres R, Martin RM, Johansson M, Brennan P. Commentary: What

can Mendelian randomization tell us about causes of cancer? International Journal of

804 Epidemiology. 2019;48(3):816-21. doi: 10.1093/ije/dyz151.

805 59. Morris TT, Heron J, Sanderson E, Smith GD, Tilling K. Interpretation of mendelian

⁸⁰⁶ randomization using one measure of an exposure that varies over time. medRxiv.

2021:2021.11.18.21266515. doi: 10.1101/2021.11.18.21266515.

808 60. Poddar M, Chetty Y, Chetty VT. How does obesity affect the endocrine system? A

narrative review. Clinical Obesity. 2017;7(3):136-44. doi: <u>https://doi.org/10.1111/cob.12184</u>.

61. Danforth KN, Eliassen AH, Tworoger SS, Missmer SA, Barbieri RL, Rosner BA, et al. The

association of plasma androgen levels with breast, ovarian and endometrial cancer risk factors

among postmenopausal women. International journal of cancer. 2010;126(1):199-207. doi:

813 10.1002/ijc.24709. PubMed PMID: 19569181.

814 62. Penttilä T-L, Koskinen P, Penttilä T-A, Anttila L, Irjala K. Obesity regulates bioavailable

testosterone levels in women with or without polycystic ovary syndrome. Fertility and Sterility.

816 1999;71(3):457-61. doi: https://doi.org/10.1016/S0015-0282(98)00473-7.

- 63. Lim SS, Norman RJ, Davies MJ, Moran LJ. The effect of obesity on polycystic ovary
- syndrome: a systematic review and meta-analysis. Obesity Reviews. 2013;14(2):95-109. doi:
- https://doi.org/10.1111/j.1467-789X.2012.01053.x.
- 820 64. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL. A prospective longitudinal study

of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin

levels through the menopause transition. J Clin Endocrinol Metab. 2000;85(8):2832-8. Epub

2000/08/18. doi: 10.1210/jcem.85.8.6740. PubMed PMID: 10946891.

65. Upala S, Anawin S. Bariatric surgery and risk of postoperative endometrial cancer: a

systematic review and meta-analysis. Surgery for Obesity and Related Diseases. 2015;11(4):949-

55. doi: <u>https://doi.org/10.1016/j.soard.2014.09.024</u>.

827 66. Sjöström L, Gummesson A, Sjöström CD, Narbro K, Peltonen M, Wedel H, et al. Effects of

bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects

- Study): a prospective, controlled intervention trial. Lancet Oncol. 2009;10(7):653-62. Epub
- 2009/06/27. doi: 10.1016/s1470-2045(09)70159-7. PubMed PMID: 19556163.
- 831 67. Anderwald CH, Tura A, Promintzer-Schifferl M, Prager G, Stadler M, Ludvik B, et al.
- 832 Alterations in gastrointestinal, endocrine, and metabolic processes after bariatric Roux-en-Y
- gastric bypass surgery. Diabetes Care. 2012;35(12):2580-7. Epub 2012/08/28. doi:
- 10.2337/dc12-0197. PubMed PMID: 22923664; PubMed Central PMCID: PMCPMC3507557.

835 68. Sdralis E, Argentou M, Mead N, Kehagias I, Alexandridis T, Kalfarentzos F. A Prospective
836 Randomized Study Comparing Patients with Morbid Obesity Submitted to Sleeve Gastrectomy
837 With or Without Omentectomy. Obesity Surgery. 2013;23(7):965-71. doi: 10.1007/s11695-013838 0925-z.

839 69. Beiglböck H, Fellinger P, Ranzenberger-Haider T, Itariu B, Prager G, Kautzky-Willer A, et

al. Pre-operative Obesity-Associated Hyperandrogenemia in Women and Hypogonadism in Men

Have No Impact on Weight Loss Following Bariatric Surgery. Obesity Surgery. 2020;30(10):3947-

842 54. doi: 10.1007/s11695-020-04761-4.

843 70. Ernst B, Wilms B, Thurnheer M, Schultes B. Reduced circulating androgen levels after

gastric bypass surgery in severely obese women. Obes Surg. 2013;23(5):602-7. Epub

2012/11/29. doi: 10.1007/s11695-012-0823-9. PubMed PMID: 23188476.

846 71. Bastounis EA, Karayiannakis AJ, Syrigos K, Zbar A, Makri GG, Alexiou D. Sex hormone

changes in morbidly obese patients after vertical banded gastroplasty. Eur Surg Res.

1998;30(1):43-7. Epub 1998/03/11. doi: 10.1159/000008556. PubMed PMID: 9493693.

72. Dashti SG, English DR, Simpson JA, Karahalios A, Moreno-Betancur M, Biessy C, et al.

Adiposity and Endometrial Cancer Risk in Postmenopausal Women: A Sequential Causal

Mediation Analysis. Cancer Epidemiol Biomarkers Prev. 2021;30(1):104-13. Epub 2020/10/04.

doi: 10.1158/1055-9965.Epi-20-0965. PubMed PMID: 33008875.

73. Pournaras DJ, Osborne A, Hawkins SC, Vincent RP, Mahon D, Ewings P, et al. Remission

of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. Ann

Surg. 2010;252(6):966-71. Epub 2010/11/26. doi: 10.1097/SLA.0b013e3181efc49a. PubMed

856 PMID: 21107106.

857 74. ter Horst KW, Gilijamse PW, Koopman KE, de Weijer BA, Brands M, Kootte RS, et al.

Insulin resistance in obesity can be reliably identified from fasting plasma insulin. International
Journal of Obesity. 2015;39(12):1703-9. doi: 10.1038/ijo.2015.125.

860 75. Brochu M, Mathieu M-E, Karelis AD, Doucet É, Lavoie M-E, Garrel D, et al. Contribution

of the Lean Body Mass to Insulin Resistance in Postmenopausal Women With Visceral Obesity:

A Monet Study. Obesity. 2008;16(5):1085-93. doi: <u>https://doi.org/10.1038/oby.2008.23</u>.

76. Trapp EG, Chisholm DJ, Freund J, Boutcher SH. The effects of high-intensity intermittent
exercise training on fat loss and fasting insulin levels of young women. International Journal of
Obesity. 2008;32(4):684-91. doi: 10.1038/sj.ijo.0803781.

866 77. Ross R, Janssen I, Dawson J, Kungl A-M, Kuk JL, Wong SL, et al. Exercise-Induced

Reduction in Obesity and Insulin Resistance in Women: a Randomized Controlled Trial. Obesity

868 Research. 2004;12(5):789-98. doi: <u>https://doi.org/10.1038/oby.2004.95</u>.

78. Wei S, Schmidt MD, Dwyer T, Norman RJ, Venn AJ. Obesity and Menstrual Irregularity:

Associations With SHBG, Testosterone, and Insulin. Obesity. 2009;17(5):1070-6. doi:

871 https://doi.org/10.1038/oby.2008.641.

79. Tchernof A, Després J-P. Sex steroid hormones, sex hormone-binding globulin, and

obesity in men and women. Hormone and Metabolic Research. 2000;32(11/12):526-36.

874 80. Henderson BE, Ross RK, Pike MC, Casagrande JT. Endogenous hormones as a major

factor in human cancer. Cancer Res. 1982;42(8):3232-9. Epub 1982/08/01. PubMed PMID:

876 **7046921**.

877 81. Key TJ, Pike MC. The dose-effect relationship between 'unopposed' oestrogens and

878 endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br

J Cancer. 1988;57(2):205-12. Epub 1988/02/01. doi: 10.1038/bjc.1988.44. PubMed PMID:
3358913; PubMed Central PMCID: PMCPMC2246441.

82. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial
cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1531-43. Epub
2002/12/24. PubMed PMID: 12496040.

83. Bélanger C, Luu-The V, Dupont P, Tchernof A. Adipose tissue intracrinology: potential
importance of local androgen/estrogen metabolism in the regulation of adiposity. Horm Metab
Res. 2002;34(11-12):737-45. Epub 2003/03/28. doi: 10.1055/s-2002-38265. PubMed PMID:
12660892.

888 84. Somboonporn W, Davis SR. Testosterone Effects on the Breast: Implications for 889 Testosterone Therapy for Women. Endocrine Reviews. 2004;25(3):374-88. doi:

890 **10.1210/er.2003-0016**.

891 85. Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, et al. Regulation of Aromatase

892 Expression in Estrogen-Responsive Breast and Uterine Disease: From Bench to Treatment.

⁸⁹³ Pharmacological Reviews. 2005;57(3):359-83. doi: 10.1124/pr.57.3.6.

894 86. Simó R, Sáez-López C, Barbosa-Desongles A, Hernández C, Selva DM. Novel insights in
895 SHBG regulation and clinical implications. Trends Endocrinol Metab. 2015;26(7):376-83. Epub
896 2015/06/06. doi: 10.1016/j.tem.2015.05.001. PubMed PMID: 26044465.

897 87. Grasa MDM, Gulfo J, Camps N, Alcalá R, Monserrat L, Moreno-Navarrete JM, et al.

898 Modulation of SHBG binding to testosterone and estradiol by sex and morbid obesity. Eur J

Endocrinol. 2017;176(4):393-404. Epub 2017/01/13. doi: 10.1530/eje-16-0834. PubMed PMID:

900 **28077498**.

88. Suba Z. Interplay between insulin resistance and estrogen deficiency as co- activators in

⁹⁰² carcinogenesis. Pathol Oncol Res. 2012;18(2):123-33. Epub 2011/10/11. doi: 10.1007/s12253-

903 011-9466-8. PubMed PMID: 21984197.

- 89. Maturana MA, Spritzer PM. Association between hyperinsulinemia and endogenous
- androgen levels in peri- and postmenopausal women. Metabolism. 2002;51(2):238-43. doi:
- 906 https://doi.org/10.1053/meta.2002.29997.
- 907 90. Weinberg ME, Manson JE, Buring JE, Cook NR, Seely EW, Ridker PM, et al. Low sex

⁹⁰⁸ hormone–binding globulin is associated with the metabolic syndrome in postmenopausal

- women. Metabolism. 2006;55(11):1473-80. doi:
- 910 https://doi.org/10.1016/j.metabol.2006.06.017.
- 911 91. Mu N, Zhu Y, Wang Y, Zhang H, Xue F. Insulin resistance: a significant risk factor of

endometrial cancer. Gynecol Oncol. 2012;125(3):751-7. Epub 2012/03/28. doi:

913 10.1016/j.ygyno.2012.03.032. PubMed PMID: 22449736.

914 92. Haeusler RA, McGraw TE, Accili D. Biochemical and cellular properties of insulin receptor

signalling. Nature Reviews Molecular Cell Biology. 2018;19(1):31-44. doi: 10.1038/nrm.2017.89.

- 916 93. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, et al. A prospective
- evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer.
- ⁹¹⁸ Cancer epidemiology, biomarkers & prevention : a publication of the American Association for
- ⁹¹⁹ Cancer Research, cosponsored by the American Society of Preventive Oncology.
- 2008;17(4):921-9. doi: 10.1158/1055-9965.EPI-07-2686. PubMed PMID: 18398032.

921	94.	Ogawa K	, Sun C	, Horii A. E	ploration of	genetic al	lterations in	human end	dometrial	cancer
-----	-----	---------	---------	--------------	--------------	------------	---------------	-----------	-----------	--------

- ⁹²² and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT
- ⁹²³ cascade. Oncol Rep. 2005;14(6):1481-5. Epub 2005/11/08. PubMed PMID: 16273242.
- 924 95. Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in
- 925 endometrial cancer. Clin Cancer Res. 2012;18(21):5856-64. Epub 2012/10/20. doi:
- 926 10.1158/1078-0432.Ccr-12-0662. PubMed PMID: 23082003.
- 927 96. Weigelt B, Warne PH, Lambros MB, Reis-Filho JS, Downward J. PI3K Pathway
- ⁹²⁸ Dependencies in Endometrioid Endometrial Cancer Cell Lines. Clinical Cancer Research.
- 929 2013;19(13):3533-44. doi: 10.1158/1078-0432.Ccr-12-3815.
- 930 97. Phillips AN, Smith GD. How independent are "independen" effects? relative risk
- estimation when correlated exposures are measured imprecisely. Journal of Clinical
- 932 Epidemiology. 1991;44(11):1223-31. doi: 10.1016/0895-4356(91)90155-3.
- 933 98. Subramaniam KS, Tham ST, Mohamed Z, Woo YL, Mat Adenan NA, Chung I. Cancer-
- associated fibroblasts promote proliferation of endometrial cancer cells. PLoS One.
- 2013;8(7):e68923. Epub 2013/08/08. doi: 10.1371/journal.pone.0068923. PubMed PMID:
- 23922669; PubMed Central PMCID: PMCPMC3724864.
- 937 99. Subramaniam KS, Omar IS, Kwong SC, Mohamed Z, Woo YL, Mat Adenan NA, et al.
- ⁹³⁸ Cancer-associated fibroblasts promote endometrial cancer growth via activation of interleukin-
- 939 6/STAT-3/c-Myc pathway. Am J Cancer Res. 2016;6(2):200-13. Epub 2016/05/18. PubMed
- 940 PMID: 27186396; PubMed Central PMCID: PMCPMC4859653.

100. Renehan AG, Soerjomataram I, Tyson M, Egger M, Zwahlen M, Coebergh JW, et al.

⁹⁴² Incident cancer burden attributable to excess body mass index in 30 European countries.

943 International Journal of Cancer. 2010;126(3):692-702. doi: <u>https://doi.org/10.1002/ijc.24803</u>.

101. Ochner CN, Tsai AG, Kushner RF, Wadden TA. Treating obesity seriously: when

⁹⁴⁵ recommendations for lifestyle change confront biological adaptations. The Lancet Diabetes &

946 Endocrinology. 2015;3(4):232-4. doi: 10.1016/S2213-8587(15)00009-1.

102. Evert AB, Franz MJ. Why Weight Loss Maintenance Is Difficult. Diabetes Spectrum.

948 2017;30(3):153-6. doi: 10.2337/ds017-0025.

103. Abarca-Gómez L, Abdeen ZA, Hamid ZA, Abu-Rmeileh NM, Acosta-Cazares B, Acuin C, et

al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to

2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million

⁹⁵² children, adolescents, and adults. The Lancet. 2017;390(10113):2627-42. doi: 10.1016/S0140-

953 **6736(17)32129-3**.

104. Wang Y, Beydoun MA, Min J, Xue H, Kaminsky LA, Cheskin LJ. Has the prevalence of

overweight, obesity and central obesity levelled off in the United States? Trends, patterns,

disparities, and future projections for the obesity epidemic. International Journal of

957 Epidemiology. 2020;49(3):810-23. doi: 10.1093/ije/dyz273.

105. Pineda E, Sanchez-Romero LM, Brown M, Jaccard A, Jewell J, Galea G, et al. Forecasting

⁹⁵⁹ Future Trends in Obesity across Europe: The Value of Improving Surveillance. Obesity Facts.

960 2018;11(5):360-71. doi: 10.1159/000492115.

106. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated

protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167-74. Epub

2001/10/17. doi: 10.1172/jci13505. PubMed PMID: 11602624; PubMed Central PMCID:
PMCPMC209533.

107. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, et al.
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program

967 Outcomes Study. Lancet. 2009;374(9702):1677-86. Epub 2009/11/03. doi: 10.1016/s0140-

968 6736(09)61457-4. PubMed PMID: 19878986; PubMed Central PMCID: PMCPMC3135022.

108. Boccardo F, Guarneri D, Rubagotti A, Casertelli GL, Bentivoglio G, Conte N, et al.

970 Endocrine effects of tamoxifen in postmenopausal breast cancer patients. Tumori.

971 1984;70(1):61-8. Epub 1984/02/29. PubMed PMID: 6538707.

109. Hu R, Hilakivi-Clarke L, Clarke R. Molecular mechanisms of tamoxifen-associated

973 endometrial cancer (Review). Oncol Lett. 2015;9(4):1495-501. Epub 2015/03/20. doi:

10.3892/ol.2015.2962. PubMed PMID: 25788989; PubMed Central PMCID: PMCPMC4356269.

110. Fleming CA, Heneghan HM, O'Brien D, McCartan DP, McDermott EW, Prichard RS. Meta-

analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial

surveillance in extended tamoxifen therapy. British Journal of Surgery. 2018;105(9):1098-106.

978 doi: 10.1002/bjs.10899.

111. Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L. Mitotane associated with etoposide,

980 doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Cancer.

981 1998;83(10):2194-200. doi: https://doi.org/10.1002/(SICI)1097-

982 0142(19981115)83:10<2194::AID-CNCR19>3.0.CO;2-3.

112. Theile D, Haefeli WE, Weiss J. Effects of adrenolytic mitotane on drug elimination

984 pathways assessed in vitro. Endocrine. 2015;49(3):842-53. doi: 10.1007/s12020-014-0517-2.

985	113. Farland LV, Mu F, Eliassen AH, Hankinson SE, Tworoger SS, Barbieri RL, et al. Menstrual
986	cycle characteristics and steroid hormone, prolactin, and growth factor levels in premenopausa
987	women. Cancer Causes Control. 2017;28(12):1441-52. Epub 2017/11/01. doi: 10.1007/s10552-
988	017-0971-2. PubMed PMID: 29086892; PubMed Central PMCID: PMCPMC5718047.
989	114. Janda M, Robledo KP, Gebski V, Armes JE, Alizart M, Cummings M, et al. Complete
990	pathological response following levonorgestrel intrauterine device in clinically stage 1
991	endometrial adenocarcinoma: Results of a randomized clinical trial. Gynecologic Oncology.
992	2021;161(1):143-51. doi: <u>https://doi.org/10.1016/j.ygyno.2021.01.029</u> .
993	115. Barr CE, Ryan NAJ, Derbyshire AE, Wan YL, MacKintosh ML, McVey RJ, et al. Weight Loss
994	During Intrauterine Progestin Treatment for Obesity-associated Atypical Hyperplasia and Early-
995	Stage Cancer of The Endometrium. Cancer Prev Res (Phila). 2021;14(11):1041-50. Epub
996	2021/08/06. doi: 10.1158/1940-6207.Capr-21-0229. PubMed PMID: 34348914.
997	116. Lagou V, Mägi R, Hottenga J-J, Grallert H, Perry JRB, Bouatia-Naji N, et al. Sex-dimorphic
998	genetic effects and novel loci for fasting glucose and insulin variability. Nature Communications
999	2021;12(1):24. doi: 10.1038/s41467-020-19366-9.
1000	117. Chen J, Spracklen CN, Marenne G, Varshney A, Corbin LJ, Luan Ja, et al. The trans-
1001	ancestral genomic architecture of glycemic traits. Nature Genetics. 2021;53(6):840-60. doi:
1002	10.1038/s41588-021-00852-9.
1003	118. Larsson SC, Carter P, Vithayathil M, Kar S, Mason AM, Burgess S. Insulin-like growth
1004	factor-1 and site-specific cancers: A Mendelian randomization study. Cancer Medicine.
1005	2020;9(18):6836-42. doi: <u>https://doi.org/10.1002/cam4.3345</u> .

1006	119.	Locke AE, Steinberg KM, Chiang CWK, Service SK, Havulinna AS, Stell L, et al. Exome
1007	sequer	cing of Finnish isolates enhances rare-variant association power. Nature.
1008	2019;5	72(7769):323-8. Epub 2019/07/31. doi: 10.1038/s41586-019-1457-z. PubMed PMID:
1009	313670	044.
1010	120.	Folkersen L, Gustafsson S, Wang Q, Hansen DH, Hedman ÅK, Schork A, et al. Genomic
1011	evaluat	tion of circulating proteins for drug target characterisation and precision medicine.
1012	bioRxiv	. 2020:2020.04.03.023804. doi: 10.1101/2020.04.03.023804.
1013	121.	C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC). Association
1014	betwee	en C reactive protein and coronary heart disease: mendelian randomisation analysis
1015	based	on individual participant data. BMJ. 2011;342:d548. doi: 10.1136/bmj.d548.

1017 Figure Legends:

- Fig 1. Flowchart detailing the process of identifying previously reported risk factors with suitable
 genetic instruments.
- 1020 TNF- α = tumour necrosis factor- α , IGFBP-1 = insulin-like growth factor-binding protein-1, LDL = low-
- density lipoprotein, HDL = high-density lipoprotein, IGF-1 = insulin-like growth factor-1, IL-6 =
- interleukin-6, CRP = C-reactive protein, SHBG = sex hormone-binding globulin.

1023

1024 Fig 2. DAG demonstrating the core assumptions of Mendelian randomization.

DAG = directed acyclic diagram, G = genetic instrument, E = exposure, O = outcome, C = confounding 1025 factors. Arrows labelled 1, 2, and 3 represent the three core assumptions of MR: (1) the instrument 1026 strongly associates with the exposure ("relevance"); (2) there is no confounding of the instrument-1027 1028 outcome relationship ("exchangeability"); and (3) the instrument only affects the outcome through the exposure ("exclusion restriction"). MR uses genetic instruments to proxy exposures in order to 1029 strengthen causal inference in observational epidemiological settings. As these genetic instruments are 1030 randomly inherited at meiosis, they should not be affected by conventional confounding factors like 1031 environmental, lifestyle, and behavioural traits. In addition, since germline genetic variants are fixed at 1032 1033 conception and cannot be altered by subsequent exposures, they are not susceptible to reverse 1034 causation. Finally, germline genotype can be measured relatively precisely using modern genotyping technologies which minimises measurement error. Collectively, these properties of germline genetic 1035 variants (along with technologies that measure them) permit MR analyses to minimise many of the 1036 sources of bias which can undermine robust causal inference in conventional observational 1037 epidemiological analyses. 1038 1039

1029

1041	Fig 3. DAG demonstrating the proposed causal interactions of BMI, SHBG, fasting insulin, and
1042	bioavailable testosterone on endometrial cancer (overall and the endometrioid histological subtype).
1043	DAG = directed acyclic diagram, BMI = body mass index, SHBG = sex hormone-binding globulin.
1044	
1045	Fig 4. Mendelian randomization analysis of BMI on overall and subtype-specific endometrial cancer
1046	risk.
1047	Results of MR analyses examining the effect of adult BMI on risk of overall and subtype-specific
1048	endometrial cancer risk.
1049	
1050	Fig 5. Mendelian randomization analysis of total serum cholesterol, fasting insulin, total testosterone,
1051	bioavailable testosterone, and sex hormone-binding globulin (SHBG) on overall and endometrioid
1052	endometrial cancer risk.
1053	LDL = low-density lipoprotein, HDL = high-density lipoprotein, IGF-1 = insulin-like growth factor-1, IL-6 =
1054	interleukin-6, CRP = C-reactive protein, SHBG = sex hormone-binding globulin. (A) Results of MR analyses
1055	examining the effects of previously reported molecular risk factors on risk of overall endometrial cancer
1056	risk. (B) Results of MR analyses examining the effects of previously reported molecular risk factors on
1057	risk of endometrioid subtype endometrial cancer risk.
1058	
1059	Fig 6. Mendelian randomization analysis of adult BMI on previously reported endometrial cancer risk
1060	factors.
1061	SHBG = sex hormone-binding globulin, LDL = low-density lipoprotein, CRP = C-reactive protein.

Table 1. Details of the instruments used for exposures.

Exposure	GWAS	Sample size	Number of SNPs	R ²	F-statistic	Sex-specificity
Adult BMI	Yengo et al. [42]	681,275	507	0.078	57,847	Combined
LDL-cholesterol	Willer et al. [34]	188,577	81	0.182	15,002	Combined
HDL-cholesterol	Willer et al. [34]	188,577	89	0.055	10,978	Combined
Triglyceride	Willer et al. [34]	188,577	55	0.052	9,811	Combined
Total serum	Willer et al. [34]	188,577	88	0.063	12,696	Combined
cholesterol						
Glucose	Neale et al. [36]	361,194	109	0.036	11,776	Female
Fasting insulin	Lagou et al. [116]	98,210	14	0.005	523	Combined
(unadjusted for						
BMI)						
Fasting insulin	Chen et al. [117]	150,571	14	0.006	865	Combined
(adjusted for						
BMI)						
IGF-1 (cis and	Sinnott-Armstrong	358,072	413	0.036	13,367	Combined
trans variants)	et al. [37]					
IGF-1 (cis	Larsson et al.	358,072	1	0.002	814	Combined
variants)	[118]					

IL-6	Georgakis et al.	204,402	7	0.004	911	Combined
	[38]					
Adiponectin (cis	Locke et al. [119]	14,172	3	0.023	328	Combined
and trans						
variants)						
Adiponectin (cis	Locke et al. [119]	14,172	3	0.023	334	Combined
variants)						
Lootin	Folkerson et al	20.021	1	0.001	34	Combined
Leptin	Folkersen et al. [120]	30,931	1	0.001	54	Combined
	[120]					
CRP (cis and	Ligthart et al. [41]	204,402	45	0.035	7,414	Combined
trans variants)						
CRP (cis	C Reactive Protein	105,476	4	0.010	1,030	Combined
variants)	Coronary Heart					
	Disease Genetics					
	Collaboration					
	(CCGC) [121]					
Total	Ruth et al. [29]	230,454	131	0.052	10,103	Female
testosterone						
Bioavailable	Ruth et al. [29]	188,507	147	0.054	10,599	Female
testosterone						

SHBG	Ruth et al. [29]	189,473	215	0.122	26,286	Female
------	------------------	---------	-----	-------	--------	--------

1063	BMI is scaled to an SD increase (4.7 kg/m 2). For the analysis involving the plasma proteome, due to the
1064	requirement of increased statistical power in order to overcome the multiple testing burden, alternative
1065	summary genetic association data for BMI were obtained from a genome-wide association study of
1066	681,275 individuals of European ancestry (note that this summary genetic data could not be used for
1067	other analyses due to substantial overlap of participants with summary genetic data of other traits) [42].
1068	The CRP GWAS included some individuals of non-European ancestry and adjusted for ancestry where
1069	applicable. BMI = body mass index, LDL = low-density lipoprotein, HDL = high density lipoprotein, IGF-1 =
1070	Insulin-like growth factor-1, IL-6 = interleukin-6, CRP = C-reactive protein, SHBG = sex hormone-binding
1071	globulin, LD = linkage disequilibrium. For instrument construction of IGF-1 (cis and trans variants), a P
1072	value of 5 x 10^{-6} was used.

1073 Table 2. Results of MR analyses examining the effect of adult BMI on risk of overall and subtype-

Outcome	Method	OR (95% CI)	P value
Overall	IVW	1.88 (1.69 to 2.09)	3.87 x 10 ⁻³¹
endometrial	Weighted median	1.89 (1.58 to 2.26)	5.18 x 10 ⁻¹²
cancer	Weighted mode	1.82 (1.35 to 2.44)	9.88 x 10 ⁻⁵
	MR Egger	2.03 (1.54 to 2.67)	8.41 x 10 ⁻⁷
Endometrioid	IVW	1.89 (1.65 to 2.16)	1.67 x 10 ⁻²⁰
endometrial	Weighted median	1.99 (1.60 to 2.46)	3.24 x 10 ⁻¹⁰
cancer	Weighted mode	1.96 (1.42 to 2.69)	4.67 x 10 ⁻⁵
	MR Egger	2.15 (1.52 to 3.03)	1.74 x 10 ⁻⁵
Non-endometrioi	d IVW	1.67 (1.19 to 2.35)	3.03 x 10 ⁻³
endometrial	Weighted median	2.29 (1.24 to 4.22)	8.24 x 10 ⁻³
cancer	Weighted mode	1.89 (0.77 to 4.63)	1.63 x 10 ⁻¹
	MR Egger	2.25 (0.99 to 5.07)	5.28 x 10 ⁻²

1074 specific endometrial cancer risk

ORs are shown per increase in SD (4.7 kg/m²) BMI. BMI = body mass index, IVW = inverse-variance

1076 weighted.

1078 Table 3. Results of MR analyses examining the effect of previously reported and novel potential

1079 molecular risk factors and overall and endometrioid subtype endometrial cancer risk.

Exposure	Outcome	Method	OR (95% CI)	P value
LDL-	Overall endometrial cancer	IVW	0.95 (0.87 to 1.04)	3.05 x 10 ⁻¹
cholesterol		Weighted median	0.92 (0.82 to 1.03)	1.31 x 10 ⁻¹
		Weighted mode	0.91 (0.82 to 1.02)	9.54 x 10 ⁻²
		MR Egger	0.90 (0.79 to 1.03)	1.35 x 10 ⁻¹
	Endometrioid endometrial cancer	IVW	0.98 (0.89 to 1.08)	6.70 x 10 ⁻¹
		Weighted median	0.96 (0.84 to 1.10)	5.61 x 10 ⁻¹
		Weighted mode	0.93 (0.83 to 1.06)	2.79 x 10 ⁻¹
		MR Egger	0.93 (0.81 to 1.07)	3.31 x 10 ⁻¹
HDL-	Overall endometrial cancer	IVW	1.09 (0.97 to 1.23)	1.48 x 10 ⁻¹
cholesterol		Weighted median	1.10 (0.96 to 1.26)	1.89 x 10 ⁻¹
		Weighted mode	1.07 (0.94 to 1.23)	3.11 x 10 ⁻¹
		MR Egger	1.08 (0.86 to 1.35)	4.99 x 10 ⁻¹
	Endometrioid endometrial cancer	IVW	1.04 (0.90 to 1.19)	6.05 x 10 ⁻¹
		Weighted median	0.99 (0.84 to 1.16)	8.76 x 10 ⁻¹
		Weighted mode	1.03 (0.88 to 1.21)	7.23 x 10 ⁻¹
		MR Egger	0.92 (0.71 to 1.20)	5.61 x 10 ⁻¹
Triglyceride	Overall endometrial cancer	IVW	0.95 (0.84 to 1.06)	3.55 x 10 ⁻¹
		Weighted median	0.87 (0.75 to 1.01)	7.75 x 10 ⁻²
		Weighted mode	0.91 (0.79 to 1.04)	1.61 x 10 ⁻¹
		MR Egger	0.83 (0.69 to 1.00)	6.03 x 10 ⁻²
	Endometrioid endometrial cancer	IVW	0.95 (0.83 to 1.09)	4.65 x 10 ⁻¹

		Weighted median	0.92 (0.78 to 1.08)	3.21 x 10 ⁻¹
		Weighted mode	0.91 (0.77 to 1.08)	2.87 x 10 ⁻¹
		MR Egger	0.87 (0.70 to 1.07)	2.02 x 10 ⁻¹
Total serum	Overall endometrial cancer	IVW	0.90 (0.81 to 1.00)	4.01 x 10 ⁻²
cholesterol		Weighted median	0.80 (0.71 to 0.90)	2.08 x 10 ⁻⁴
		Weighted mode	0.82 (0.73 to 0.91)	5.97 x 10 ⁻⁴
		MR Egger	0.84 (0.71 to 0.98)	3.09 x 10 ⁻²
	Endometrioid endometrial cancer	IVW	0.91 (0.82 to 1.02)	9.31 x 10 ⁻²
		Weighted median	0.81 (0.71 to 0.93)	3.40 x 10 ⁻³
		Weighted mode	0.84 (0.74 to 0.97)	1.64 x 10 ⁻²
		MR Egger	0.86 (0.72 to 1.01)	7.60 x 10 ⁻²
Glucose	Overall endometrial cancer	IVW	0.95 (0.79 to 1.14)	5.64 x 10 ⁻¹
		Weighted median	0.97 (0.80 to 1.17)	7.36 x 10 ⁻¹
		Weighted mode	0.93 (0.78 to 1.11)	4.47 x 10 ⁻¹
		MR Egger	0.99 (0.73 to 1.34)	9.29 x 10 ⁻¹
	Endometrioid endometrial cancer	IVW	0.90 (0.73 to 1.11)	3.26 x 10 ⁻¹
		Weighted median	0.98 (0.77 to 1.23)	8.31 x 10 ⁻¹
		Weighted mode	0.98 (0.80 to 1.20)	8.29 x 10 ⁻¹
		MR Egger	0.94 (0.67 to 1.33)	7.39 x 10 ⁻¹
Fasting	Overall endometrial cancer	IVW	3.93 (2.29 to 6.74)	7.18 x 10 ⁻⁷
insulin		Weighted median	3.49 (1.60 to 7.62)	1.67 x 10 ⁻³
		Weighted mode	3.55 (0.85 to 14.78)	1.06 x 10 ⁻¹
		MR Egger	8.28 (0.67 to 102.10)	1.25 x 10 ⁻¹
	Endometrioid endometrial cancer	IVW	4.64 (2.30 to 9.36)	1.84 x 10 ⁻⁵

		Weighted median	3.93 (1.56 to 9.93)	3.80 x 10 ⁻³
		Weighted mode	3.28 (0.69 to 15.62)	1.61 x 10 ⁻¹
		MR Egger	21.59 (0.78 to 593.93)	9.66 x 10 ⁻²
IGF-1 (cis and	Overall endometrial cancer	IVW	0.93 (0.85 to 1.06)	2.60 x 10 ⁻¹
trans		Weighted median	1.01 (0.85 to 1.20)	8.96 x 10 ⁻¹
variants)		Weighted mode	1.22 (0.89 to 1.67)	2.28 x 10 ⁻¹
		MR Egger	1.17 (0.85 to 1.60)	3.49 x 10⁻¹
	Endometrioid endometrial cancer	IVW	0.89 (0.77 to 1.03)	1.12 x 10 ⁻¹
		Weighted median	1.03 (0.84 to 1.25)	8.06 x 10 ⁻¹
		Weighted mode	1.32 (0.92 to 1.90)	1.30 x 10 ⁻¹
		MR Egger	1.22 (0.85 to 1.76)	2.75 x 10 ⁻¹
IGF-1 (cis	Overall endometrial cancer	Wald ratio	1.20 (0.79 to 1.82)	3.92 x 10 ⁻¹
variants)	Endometrioid endometrial cancer	Wald ratio	1.40 (0.85 to 2.28)	1.84 x 10 ⁻¹
IL-6 (scaled	Overall endometrial cancer	IVW	0.90 (0.66 to 1.21)	4.80 x 10 ⁻¹
to natural log	Endometrioid endometrial cancer	IVW	0.86 (0.60 to 1.23)	4.01 x 10 ⁻¹
transformed				
mg/L change				
in CRP)				
Adiponectin	Overall endometrial cancer	IVW	0.92 (0.79 to 1.08)	3.17 x 10 ⁻¹
(cis and trans	Endometrioid endometrial cancer	IVW	0.94 (0.78 to 1.13)	4.99 x 10 ⁻¹
variants)				
Adiponectin	Overall endometrial cancer	IVW	0.95 (0.83 to 1.08)	3.94 x 10 ⁻¹
(cis variants)	Endometrioid endometrial cancer	IVW	1.00 (0.86 to 1.16)	9.92 x 10 ⁻¹
Leptin	Overall endometrial cancer	Wald Ratio	1.03 (0.68 to 1.54)	8.96 x 10 ⁻¹

	Endometrioid endometrial cancer	Wald Ratio	0.88 (0.54 to 1.42)	5.99 x 10 ⁻¹
CRP (cis and	Overall endometrial cancer	IVW	1.07 (0.94 to 1.22)	3.03 x 10 ⁻¹
trans		Weighted median	0.97 (0.84 to 1.12)	6.76 x 10 ⁻¹
variants)		Weighted mode	1.02 (0.91 to 1.14)	7.80 x 10 ⁻¹
		MR Egger	0.96 (0.80 to 1.16)	6.99 x 10⁻¹
	Endometrioid endometrial cancer	IVW	1.12 (0.96 to 1.30)	1.39 x 10 ⁻¹
		Weighted median	1.03 (0.87 to 1.23)	6.92 x 10 ⁻¹
		Weighted mode	1.04 (0.90 to 1.20)	6.34 x 10 ⁻¹
		MR Egger	0.97 (0.78 to 1.20)	7.69 x 10 ⁻¹
CRP (cis	Overall endometrial cancer	IVW	0.98 (0.85 to 1.13)	7.52 x 10 ⁻¹
variants)	Endometrioid endometrial cancer	IVW	0.98 (0.83 to 1.16)	8.02 x 10 ⁻¹
Total	Overall endometrial cancer	IVW	1.64 (1.43 to 1.88)	1.71 x 10 ⁻¹²
testosterone		Weighted median	1.67 (1.39 to 2.01)	3.95 x 10 ⁻⁸
		Weighted mode	1.74 (1.38 to 2.20)	8.33 x 10⁻ ⁶
		MR Egger	1.81 (1.38 to 2.38)	4.17 x 10 ⁻⁵
	Endometrioid endometrial cancer	IVW	1.60 (1.36 to 1.87)	8.70 x 10 ⁻⁹
		Weighted median	1.81 (1.45 to 2.26)	2.05 x 10 ⁻⁷
		Weighted mode	1.88 (1.42 to 2.48)	2.34 x 10 ⁻⁵
		MR Egger	1.74 (1.26 to 2.41)	1.02 x 10 ⁻³
Bioavailable	Overall endometrial cancer	IVW	1.46 (1.29 to 1.65)	3.48 x 10 ⁻⁹
testosterone		Weighted median	1.47 (1.20 to 1.82)	2.46 x 10 ⁻⁴
		Weighted mode	1.51 (1.19 to 1.93)	1.16 x 10 ⁻³
		MR Egger	1.90 (1.46 to 2.47)	5.63 x 10 ⁻⁶
	Endometrioid endometrial cancer	IVW	1.46 (1.26 to 1.69)	3.08 x 10 ⁻⁷

		Weighted median	1.42 (1.14 to 1.76)	1.97 x 10 ⁻³
		Weighted mode	1.60 (1.20 to 2.13)	1.59 x 10 ⁻³
SHBG	Overall endometrial cancer	MR Egger	1.79 (1.31 to 2.43)	3.08 x 10 ⁻⁷
		IVW	0.71 (0.59 to 0.85)	2.07 x 10 ⁻⁴
		Weighted median	0.64 (0.48 to 0.86)	2.54 x 10 ⁻³
		Weighted mode	0.69 (0.53 to 0.89)	4.97 x 10 ⁻³
	Endometrioid endometrial cancer	MR Egger	0.62 (0.46 to 0.84)	2.52 x 10 ⁻³
		IVW	0.65 (0.54 to 0.80)	3.31 x 10 ⁻⁵
		Weighted median	0.60 (0.43 to 0.86)	4.90 x 10 ⁻³
		Weighted mode	0.58 (0.40 to 0.82)	2.50 x 10 ⁻³
		MR Egger	0.61 (0.44 to 0.84)	3.33 x 10 ⁻³

1080 ORs are shown per increase in inverse normal transformed nmol/L SHBG, natural log transformed pmol/L fasting insulin, inverse normal transformed nmol/L total testosterone, inverse normal 1081 transformed nmol/L bioavailable testosterone, SD (38.7 mg/dL) LDL-cholesterol, nmol/L IGF-1, mmol/L 1082 blood glucose, natural log transformed CRP mg/L IL-6, natural log transformed ug/ml adiponectin for 1083 1084 combined instrument, natural log transformed ug/ml cis-only adiponectin, natural log transformed mg/L 1085 CRP, mg/dL triglyceride, SD (41.7 mg/dL) total serum cholesterol, mg/dL HDL-cholesterol, pg/mL leptin. LDL = low-density lipoprotein, HDL = high density lipoprotein, IGF-1 = Insulin-like growth factor-1, IL-6 = 1086 interleukin-6, CRP = C-reactive protein, SHBG = sex hormone-binding globulin, IVW = inverse-variance 1087 weighted. For instrument construction of IGF-1 (cis and trans variants), a P value of 5×10^{-6} was used. 1088 1089

1090 Table 4. Results of MR analyses examining the effect of BMI on previously reported molecular risk

1091 factors.

Outcome	Method	Effect estimate (95% Cl)	P value
Total serum cholesterol	IVW	-0.03 (-0.06 to 0.01)	1.22 x 10 ⁻¹
	Weighted median	-0.06 (-0.11 to -0.01)	2.98 x 10 ⁻²
	Weighted mode	-0.08 (-0.15 to 0.00)	4.46 x 10 ⁻²
	MR Egger	-0.08 (-0.16 to 0.00)	3.89 x 10 ⁻²
Fasting insulin	IVW	0.17 (0.15 to 0.19)	1.51 x 10 ⁻⁷⁴
	Weighted median	0.18 (0.15 to 0.21)	8.51 x 10 ⁻³¹
	Weighted mode	0.18 (0.12 to 0.24)	1.88 x 10 ⁻⁹
	MR Egger	0.20 (0.16 to 0.25)	1.30 x 10 ⁻¹⁶
Total testosterone	IVW	0.08 (0.05 to 0.11)	9.04 x 10 ⁻¹⁰
	Weighted median	0.06 (0.03 to 0.09)	4.95 x 10 ⁻⁴
	Weighted mode	-0.01 (-0.08 to 0.07)	8.60 x 10 ⁻¹
	MR Egger	0.02 (-0.05 to 0.09)	5.23 x 10 ⁻¹
Bioavailable testosterone	IVW	0.26 (0.23 to 0.29)	9.97 x 10 ⁻⁶⁸
	Weighted median	0.24 (0.20 to 0.28)	1.72 x 10 ⁻³⁸
	Weighted mode	0.09 (0.01 to 0.17)	2.41 x 10 ⁻²
	MR Egger	0.16 (0.08 to 0.24)	4.36 x 10 ⁻⁵
SHBG	IVW	-0.17 (-0.19 to -0.16)	4.86 x 10 ⁻¹²⁵
	Weighted median	-0.16 (-0.18 to -0.15)	8.85 x 10 ⁻⁷⁷
	Weighted mode	-0.15 (-0.18 to -0.12)	8.43 x 10 ⁻²⁰
	MR Egger	-0.13 (-0.17 to -0.09)	3.11 x 10 ⁻¹¹

1092	BMI is scaled to an SD increase (4.7 kg/m ²). Effect estimate represents change in SD (41.7 mg/dL) total
1093	serum cholesterol, natural log transformed pmol/L fasting insulin, inverse normal transformed nmol/L
1094	total testosterone, inverse normal transformed nmol/L bioavailable testosterone, and inverse normal
1095	transformed nmol/L SHBG. SHBG = sex hormone-binding globulin, IVW = inverse-variance weighted.

1096 Table 5. Results of multivariable MR mediation analysis examining the effect of BMI and endometrial

1097 cancer with previously reported molecular risk factors as potential mediators.

		Direct Effect of	Indirect Effect of	% Mediated	
Mediator	Outcome		Mediator on	(95% CI)	P value
		BMI on Outcome	Outcome		
Fasting	Overall	1.75	1.07	11% (1 to 21%)	2.89 x 10 ⁻²
insulin	Endometrial Cancer				
	Endometrioid	1.72	1.11	16% (3 to 28%)	1.24 x 10 ⁻²
	Endometrial Cancer				
Bioavailable	Overall	1.70	1.11	15% (10 to 20%)	1.43 x 10 ⁻⁸
testosterone	Endometrial Cancer				
	Endometrioid	1.72	1.11	15% (9 to 22%)	2.15 x 10⁻ ⁶
	Endometrial Cancer				
SHBG	Overall	1.80	1.04	7% (1 to 12%)	1.81 x 10 ⁻²
	Endometrial Cancer				
	Endometrioid	1.86	1.02	2% (-9 to 14%)	6.87 x 10 ⁻¹
	Endometrial Cancer				

Direct effect is defined as the remaining effect of the exposure (BMI) on the outcome (endometrial cancer risk) when the effect of the candidate mediator on the outcome has been adjusted for. Indirect effect is defined as the effect of the exposure (BMI) on the outcome (endometrial cancer risk) through the candidate mediator. SHBG = sex hormone-binding globulin.

- 1102 Supporting Information Captions
- 1103 S1 Appendix. List of unique molecular traits identified from literature search.
- 1104 S2 Appendix. Supplementary methods.
- 1105 S3 Appendix. PubMed search terms for literature review.
- 1106 S4 Table. Additional information on GWAS, including covariates adjusted for.
- 1107 **S5 Table. Sample overlap between GWAS.**
- 1108 S6 Table. Conditional F-statistics for multivariable Mendelian randomization of BMI and mediators on
- 1109 endometrial cancer risk.
- S7 Figure. Leave-one-out analysis for MR examining the effect of adult BMI on overall endometrial
 cancer risk.
- 1112 S8 Table. Results of female BMI sensitivity analysis MR.
- S9 Table. Results from sensitivity analyses examining the influence of Winner's curse on GWAS with
 overlapping samples.
- S10 Figure. Leave-one-out analysis for MR examining the effect of adult BMI on endometrioid
 endometrial cancer risk.
- S11 Figure. Leave-one-out analysis for MR examining the effect of adult BMI on non-endometrioid
 endometrial cancer risk.
- S12 Figure. Leave-one-out analysis for MR examining the effect of total testosterone level on
 endometrial cancer risk.

S13 Figure. Leave-one-out analysis for MR examining the effect of bioavailable testosterone level on
 endometrial cancer risk.

S14 Figure. Leave-one-out analysis for MR examining the effect of fasting insulin level on endometrial
 cancer risk.

S15 Figure. Leave-one-out analysis for MR examining the effect of SHBG level on endometrial cancer
 risk.

1127 S16 Figure. Leave-one-out analysis for MR examining the effect of total serum cholesterol level on

1128 endometrial cancer risk.

1129 **S17** Table. Results of female-specific SNP fasting insulin sensitivity analysis MR.

1130 **S18** Table. Results of female-specific SNP CRP sensitivity analysis MR.

1131 S19 Figure. Leave-one-out analysis for MR examining the effect of total testosterone level on

- 1132 endometrioid endometrial cancer risk.
- 1133 S20 Figure. Leave-one-out analysis for MR examining the effect of bioavailable testosterone level on
- 1134 endometrioid endometrial cancer risk.

1135 S21 Figure. Leave-one-out analysis for MR examining the effect of fasting insulin level on

1136 endometrioid endometrial cancer risk.

S22 Figure. Leave-one-out analysis for MR examining the effect of SHBG level on endometrioid
 endometrial cancer risk.

1139 S23 Figure. Leave-one-out analysis for MR examining the effect of adult BMI on fasting insulin level.

1140 S24 Figure. Leave-one-out analysis for MR examining the effect of adult BMI on SHBG level.

- S25 Figure. Leave-one-out analysis for MR examining the effect of adult BMI on bioavailable
 testosterone level.
- S26 Figure. Leave-one-out analysis for MR examining the effect of adult BMI on total serum
 cholesterol level.
- S27 Figure. Leave-one-out analysis for MR examining the effect of adult BMI on C-reactive protein
 level.

1147 S28 Table. Results of female-specific SNP BMI sensitivity mediation analysis.

1148 S29 Table. Results of female-specific SNP fasting insulin mediation analysis.

1149 S30 Table. Results of multivariable MR mediation analysis examining the effect of BMI and

endometrial cancer with fasting insulin as a potential mediator with BMI-adjusted fasting insulin

- instrument and 100 SNPs from BMI instrument.
- 1152 S31 Table. Results from sensitivity analyses examining the influence of Winner's curse on GWAS with

1153 overlapping samples in analyses determining the mediating role of traits in the relationship between

1154 BMI and endometrial cancer risk.

- 1155 S32 Table. Results from sensitivity analyses examining the influence of Winner's curse on GWAS with
- 1156 overlapping samples in analyses determining the interdependent effects of mediators of the
- 1157 relationship between BMI and endometrial cancer risk.

1158 S33 Table. Conditional F-statistics for further multivariable Mendelian randomization analyses.

- 1159 S34 Table. Results of multivariable MR mediation analysis examining the effect of endometrial cancer
- 1160 with pairs of confirmed mediating molecular traits without BMI.

1161 S35 Table. Results of multivariable MR mediation analysis examining the effect of BMI and

endometrial cancer with fasting insulin as a potential mediator with 100 SNPs from BMI instrument.

1163 S36 Table. Results of multivariable MR mediation analysis examining the effect of BMI and

endometrial cancer with fasting insulin as a potential mediator with BMI-adjusted fasting insulin

1165 instrument.

S37 Table. Conditional F-statistics for fasting insulin (adjusted for BMI) and BMI with differing
 thresholds used to construct fasting insulin.

1168 S38 Table. Results of multivariable MR mediation analysis examining the effect of BMI and

endometrial cancer with all confirmed mediating molecular traits with BMI-adjusted fasting insulin.

1170 S39 Table. Results of multivariable MR mediation analysis examining the effect of BMI and

1171 endometrial cancer with pairs of confirmed mediating molecular traits.

1172 S40 Table. Results of multivariable MR mediation analysis examining the effect of BMI and

1173 endometrial cancer with all confirmed mediating molecular traits including fasting insulin adjusted for

1174 BMI with 100 SNPs from BMI instrument.

1175 S41 Table. Results of multivariable MR mediation analysis examining the effect of BMI and

endometrial cancer with pairs of confirmed mediating molecular traits with 100 SNPs from BMI

1177 instrument.


S42 Table. Results of multivariable MR mediation analysis examining the effect of endometrial cancer
 with all confirmed mediating molecular traits without BMI.

1180 S43 Table. Results of sensitivity analysis examining the effect of only including 100 SNPs for the BMI

1181 instrument in MR analyses.

- 1182 S44 Table. Conditional F-statistics with different levels of genetic correlation for SHBG and BMI in
- 1183 multivariable Mendelian randomization analyses.
- 1184 S45 Table. Results of HEIDI test-filtered low-density lipoprotein (LDL) cholesterol and overall
- 1185 endometrial cancer MR.

20 risk factors identified from two PubMed literature searches



leptin, CRP, total testosterone,

bioavailable testosterone, SHBG

Fig 1.




Fig 2.




Fig 3.




Fig 4.




Fig 5.




Fig 6.